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  ABSTRACT 
 
The purpose of this study was to investigate if the molecular weight and degree of 
sulfation of chondroitin sulfate (CS) has an impact on its in vitro absorption and anti-
inflammatory activity. 
For absorption studies, Caco-2 cells were incubated with eight CS samples of differing 
molecular weights (7 kDa - 35 kDa). The amount of CS transported into the basolateral 
side of the Caco-2 monolayer was quantitatively determined to calculate the permeability 
coefficients (Peff). The permeability coefficients of the eight different CS samples across 
Caco-2 cell monolayers were assessed. For anti-inflammatory studies, RAW 264.7 
murine macrophage cells were pre incubated with the CS samples for an hour followed 
by addition of bacterial lipopolysaccharide (LPS). The anti-inflammatory activity of CS 
samples was measured by the ability of CS samples to inhibit expression of a panel of 
inflammatory cytokines- tumor necrosis factor-alpha (TNF-α), Interleukin-1 beta (IL-1β) 
and Interleukin-6 (IL-6). These inflammatory markers were quantitatively measured 
using ELISA and inhibition of nitric oxide (NO) production was measured using Griess 
reagent assay. 
Of the eight samples evaluated, four had a Peff value of 15 x 10
-6 
cm sec
-1
 or higher 
indicating moderate to high absorption. Two of the four samples with higher Peff values 
were high molecular weight compounds (~ 35 kDa). At concentrations of 5 µg/ml as well 
as 15 µg/ml, CS samples significantly inhibited expression of LPS induced TNF-α. 
Expression of IL-6 was inhibited by some of the CS samples at 15 µg/ml concentration 
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but not at 5µg/ml. Under the experimental conditions, IL-1β and NO were not useful in 
estimating the anti-inflammatory activity of the CS samples. Statistical analysis which 
examined the relation between molecular weight and each of these inflammatory markers 
revealed no correlation (p<0.05). 
Within the CS molecular weight range used in this experiment, the absorption of CS 
samples did not have a correlation with their molecular weights but, interestingly, 
correlation was observed between the absorption and percentage of 6-sulfated 
disaccharide in the CS samples. CS samples used in this study appeared to inhibit some 
of the inflammatory cytokines but no correlation seemed to exist between the molecular 
weights and anti-inflammatory activity of these samples. 
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CHAPTER 1 
INTRODUCTION 
1.1. Arthritis: 
Arthritis is a general term for inflammation of the joints (such as the knees, wrists, 
fingers, toes, and hips) and surrounding tissues. The two more common types of arthritis 
are osteoarthritis (OA) and rheumatoid arthritis (RA) (Figure 1.1). 
 
Figure 1.1: Normal and arthritic joints. In the case of osteoarthritis, cartilage is 
degenerated and bone ends rub together while in rheumatoid arthritis bones erode with 
simultaneous inflammation in the synovial membrane. (Illustration by Pooja Puneet) 
1.1.1. Rheumatoid arthritis (RA): 
Rheumatoid arthritis is an autoimmune inflammatory disease that usually involves joints 
in the fingers, thumbs, wrists, elbows, shoulders, knees, feet, and ankles. Patients with 
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RA may also have systemic symptoms including fatigue, fever, weight loss, eye 
inflammation, anemia, pleurisy (inflammation of lining of the lungs) or subcutaneous 
nodules (Ropes, Bennett, Cobb, Jacox, & Jessar, 1957; Scadding, 1969). 
1.1.2. Osteoarthritis (OA): 
Osteoarthritis (OA) is the most common form of arthritis, and is the single most 
important cause of disability in older adults (Issa & Sharma, 2006; Peat, McCarney, & 
Croft, 2001). OA is characterized by slow degeneration of joint cartilage and the 
underlying bone with possible development of bone spurs. The degeneration of these 
tissues eventually leads to pain, and possible limited mobility of the joint. OA is 
classified into idiopathic OA (primary) or secondary OA (traumatic, congenital, 
metabolic and other medical causes). 
OA is defined as a condition of the synovial joints characterized by  loss of cartilage, 
development of osteophytes and subchondral sclerosis which is also accompanied by a 
degree of synovitis (Brooks, 2003). OA has different clinical manifestations in different 
joints of the body. The more commonly affected joints are the hands, knees, hips, and 
spine. The onset of disease is gradual and usually begins after the age of 40 (Buckwalter, 
Saltzman, & Brown, 2004).  
Incidence: 
In 2008, approximately 27 million Americans were affected by OA. This increased from 
21 million in 1990. About 13.9% adults over age 25 and 33.6% over age 65 are affected 
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(Lawrence et al., 2008). By 2030, a projected 67 million people will have physician-
diagnosed arthritis (Hootman & Helmick, 2006). Before the age of 55, OA is observed to 
occur equally in men and women. Upon reaching the age of 55, OA is occurs more 
commonly in women (Buckwalter et al., 2004). With ageing of the population, the 
importance of osteoarthritis as a cause of disability is increasing in both industrialized 
countries as well as the developing world (Brooks, 2003). In 2004, an estimated 
expenditure of  $60 billion was incurred as a result of  OA in the form of traditional 
medical costs and indirect economic and wage losses (Buckwalter et al., 2004; D. W. 
Jackson, Simon, & Aberman, 2001). This expense is projected to increase as the 
incidence of OA is estimated to double by 2030.  
Causes: 
Understanding the exact cause of OA is complicated by the number of risk factors 
involved in the incidence as well as the progressive nature of the condition. It is the 
cumulative result of several risk factors. The importance and interaction of these risk 
factors also vary depending on the anatomical site of OA. Generalized or systemic risk 
factors include- age, gender, genetic predisposition, obesity, bone mineral density and 
nutrition; while localized or biomechanical risk factors include- physical activity, joint 
alignment and trauma to the tissue.  
Symptoms: 
The early symptoms of OA are stiffness, joint pain and swelling. The pain of 
osteoarthritis is often aggravated by activity and relieved by rest. As the disease 
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progresses, it may lead to extensive changes in joint morphology due to the growth of 
bone spurs, development of muscle weakness and loss of joint integrity which eventually 
results in decreased functionality of the joint. Radiographic studies and other diagnostic 
tools such as ultrasound, computed tomography (CT) and magnetic resonance imaging 
(MRI) are useful in evaluating joint pathology and determining the extent of damage to 
the cartilage and the associated tissues. OA was commonly described as a non-
inflammatory disease in order to distinguish it from inflammatory arthritis such as RA 
(Bonnet & Walsh, 2005) . Despite this presumed distinction, there is an abundance of 
research showing close association of inflammation with symptoms and progress of OA. 
Pathophysiology: 
OA affects chondrocytes which are the cells present in joint cartilage.  In  healthy 
cartilage, these cells are in  metabolic equilibrium with constant catabolic and anabolic 
activities maintaining the structural and functional integrity of the cartilage extracellular 
matrix (ECM) (Poole, 2001). Any disturbance in this balance of anabolic and catabolic 
activities of chondrocytes is implicated in loss of the cartilage matrix that is correlated 
with development of OA (S. R. Goldring & Goldring, 2004; Shinmei & Nemoto, 1996). 
Multiple factors such as development of acquired or age-related alteration in chondrocyte 
function, effects of excessive mechanical loading, and the presence of dysregulated 
cytokine activities are likely involved in disruption of chondrocyte remodeling activities 
in OA (S. R. Goldring & Goldring, 2004).  
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Advanced studies on the pathophysiology of OA emphasize that it is not only a 
degenerative disease, but that there is an associated ongoing and underlying inflammatory 
process involved (S. B. Abramson, 2004; Brooks, 2003; Conrozier et al., 1998; 
D'Agostino et al., 2005; Ehrlich, 1975; Peyron, 1981; Spector et al., 1997). Inflammation 
may act as an important factor in promoting cartilage degradation by impairing its ability 
to repair ongoing damage (Mary B. Goldring & Otero, 2011). The inflammation present 
in OA occurs in both idiopathic OA and secondary OA (Altman & Gray, 1985). 
Inflammatory cytokines are closely associated with the functional alterations of cartilage, 
synovium and the subchondral bone observed with arthritis (Fernandes, Martel-Pelletier, 
& Pelletier, 2002; S. R. Goldring & Goldring, 2004). These cytokines also inhibit 
chondrocyte compensatory synthetic processes required to reinstate the integrity of the 
damaged ECM (Fernandes et al., 2002).  Thus, cytokines not only promote tissue damage 
and degradation but also hinder regeneration (Pelletier, Roughley, Dibattista, McCollum, 
& Martelpelletier, 1991) . Over expression of pro-inflammatory cytokines such as IL-1β 
and TNF-α seen in early stages of OA may contribute to progressive cartilage 
degradation by increased activation of interrelated pathophysiological pathways (Benito, 
Veale, Fitzgerald, van den Berg, & Bresnihan, 2005; M. B. Goldring, 2000). IL-1β and 
TNF-α  also upregulate the chondrocyte production of metalloproteinases, inducible nitric 
oxide synthase (iNOS) and free radicals, the factors associated with cartilage matrix 
destruction (Hedbom & Hauselmann, 2002). Inflammation in OA is also associated with 
angiogenesis which may contribute to pain, the major symptom of OA (Bonnet & Walsh, 
2005).  
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Treatment options: 
Currently, there is no cure for osteoarthritis. Understanding the role of inflammation in 
OA may result in better management of the disease. Current treatments for OA focus on 
pain relief and preservation of the function of the joints involved. Anti-inflammatory 
drugs have been shown to not only reduce the pain but also reduce joint tenderness and 
stiffness in patients with OA (Dieppe, 1978).  Analgesics, non-steroidal anti-
inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, and local intra-
articular steroid injections are commonly used pharmacological interventions in patients 
with OA. Therapies interfering with expression or action of proinflammatory cytokines 
IL-1β and TNF-α have been suggested as promising interventions in the management of 
OA (M. B. Goldring, 2000).  
Although use of NSAIDs relieves symptoms of OA, continuous use of these drugs is 
limited by the potential side effect of gastrointestinal (GI) toxicity (Scanzello, 
Moskowitz, & Gibofsky, 2008). Furthermore, the higher price of COX-2 inhibitors 
compared to the over the counter NSAIDs sometimes outweighs their lowered risk of GI 
toxicity. Also, the use of COX-2 inhibitors requires caution in the case of patients with 
renal and cardiovascular conditions. This scenario demands the availability of an 
alternative therapy that provides the same advantages of the above mentioned drugs 
without the dangerous side effects of long term usage. Nutritional supplements containing 
glucosamine and chondroitin sulfate have shown promising results in reducing pain and 
preserving joint functionality in people and animals with OA (Black et al., 2009). 
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Chondroitin sulfate is present in virtually all of the commercially available joint health 
supplements.  
1.2. Chondroitin sulfate: 
Chondroitin sulfate (CS) belongs to a group of compounds called glycosaminoglycans 
(GAGs). Glucosamine, often paired with CS in supplements for OA is also a GAG. 
GAGs are long unbranched/linear polysaccharides consisting of repeating disaccharide 
units of a uronic acid and an amino sugar. GAGs are primarily located in the ECM of 
connective tissue (cartilage, bone, tendons, ligaments, bone and skin) as a part of 
proteoglycans (PGs). Multiple GAGs covalently attached to a core protein backbone form 
the PGs. These connective tissues also contain collagen. In articular cartilage tissues, 
collagen contributes to the tensile strength whereas the PGs give the tissue resilience.  
Of particular interest to this dissertation is Chondroitin sulfate which is widely used in 
joint health supplements in the USA (McAlindon, LaValley, Gulin, & Felson, 2000). In 
most of the supplements it is present in combination with glucosamine and 
methylsulfonylmethane (MSM). CS has a potentially expanding market considering the 
tens of millions of Americans who suffer from OA. It is currently recommended as a 
SYSADOA (symptomatic slow acting drug for OA) by the European League Against 
Rheumatism (EULAR) based on research evidence, meta-analysis and numerous clinical 
studies and reviews (N. Volpi, 2009). 
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1.2.1. Structure & Characteristics: 
CS is present in virtually all connective tissues of the body as part of PGs. CS represents 
a highly heterogeneous group of unbranched polysaccharides characterized by alternating 
disaccharide units of N-acetyl galactosamine and glucuronic acid as seen in Figure 1.2. 
D-glucuronic acid is β-1:3 linked to N-acetyl-D-galactosamine which is in turn β-1:4 
linked to the D-glucuronic acid of adjacent disaccharide (Beaty & Mello, 1987). The 
more common and commercially available forms of CS consist of sulfated groups at 
positions C-4 or C-6 of galactosamine in the disaccharide unit. In addition to the variation 
in molecular weight, the presence of sulfate groups in different amounts and positions (2 
and 3 of β-D-glucuronic acid, and 4 and 6 of N-acetyl-galactosamine residues) also 
greatly contributes to its heterogeneity. CS originated from different tissues varies in 
terms of amount and positions of sulfation and molecular mass (Nicola Volpi, 2004).  
 
Figure 1.2: Nomenclature based on the position of sulfate group(s) in CS.  i) When 
R2=R4=R6= H: non-sulfated chondroitin (ΔDi-0s : 2-acetamido-2-deoxy-3-O-(β-D-gluco-
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4-enepyranosyluronic acid)-D-galactose); ii) when R4=SO3
-
 and R2=R6=H: Chondroitin-
4-sulfate (ΔDi-4s: 2-acetamido-2-deoxy-3-O-(β -D-gluco-4-enepyranosyluronic acid)-4-
O-sulpho-D-glactose ); and iii) when R6=SO3
- 
and R2=R4=H: Chondroitin-6-sulfate (ΔDi-
6s: 2-acetamido-2-deoxy-3-O-(β -D-gluco-4-enepyranosyluronic acid)-6-O-sulpho-D-
glactose)   
CS was first extracted and purified in the 1960s (Telser, Robinson, & Dorfman, 1965). 
Nuclear magnetic resonance (NMR) studies of CS from bovine trachea, porcine trachea 
and shark cartilage, characterized the disaccharide composition as presented in Table 1 
(Mucci, Schenetti, & Volpi, 2000). Studies on CS obtained from other sources presented 
additional variations in molecular weight as well as amount and positions of sulfation 
confirming the heterogeneity of the compound (N. Volpi, Dondi, & Bolognani, 1998).  In 
humans, the disaccharide composition of CS chains varies with age, position 
(topography) on the joint surface, and the zone of cartilage analyzed. The ratio of 6s-
disaccharide to 4s disaccharide increased with age (Bayliss, Osborne, Woodhouse, & 
Davidson, 1999). Most commercially available CS for oral supplementation is obtained 
from bovine, porcine and shark sources, although several other sources of CS such as 
shark fin cartilage, crocodile hyoid cartilage, chicken keel cartilage, etc. have also been 
explored (Garnjanagoonchorn, Wongekalak, & Engkagul, 2007; Luo, Fosmire, & Leach, 
2002; J.-S. Sim et al., 2007).  
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Table 1.1: Characteristics of CS from different sources. Adapted from (Mucci et al., 
2000). 
Characteristics 
Source 
Bovine trachea Porcine trachea Shark cartilage 
Molecular mass(kDa) 23.7±1.6 18.1±1.4 >50.0 
ΔDi-0s(wt%) 7.3±0.4 6.1±0.3 2.2±0.1 
ΔDi-4s(wt%) 51.4±3.1 66.3±3.3 27.7±1.1 
ΔDi-6s(wt%) 40.6±3.1 25.6±1.5 49.0±2.4 
ΔDi-dis+ΔDi-tris(wt%) 0.7 1.9 22.0 
4s/6s ratio 1.24±0.06 2.41±0.12 0.47±0.02 
 
1.2.2. CS in OA- Safety and efficacy: 
Several in vitro studies, animal studies and clinical trials demonstrated the role and 
efficacy of CS in management and treatment of symptoms of OA as elaborated below. 
When bovine articular chondrocytes were exposed to stimulated conditions of in vivo 
stress (mechanical, thermal and cytokine), CS enhanced the protective metabolic 
response, suggesting its role as a biological response modifier (BRM) (Lippiello, 2003). 
In cultured rabbit chondrocytes , CS reduced IL-1β induced translocation of nuclear 
factor- κB (NF-κB) by about 8% but did not prevent increase in nitric oxide (NO) 
(Jomphe et al., 2008).  
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Numerous clinical studies provided evidence suggesting that orally administered CS acts 
as a slow acting symptomatic drug in patients with OA and is safe at doses as high as 800 
– 1200 mg/day.  Two different randomized, double blind, placebo-controlled studies (one 
6-months and another one year), on patients with knee OA revealed that CS was well 
tolerated at a dosage of 800 mg/day. Further, CS showed efficacy in improving mobility 
and reducing pain (Bucsi & Poor, 1998; Uebelhart, Thonar, Delmas, Chantraine, & 
Vignon, 1998). In another 3 year randomized, double blind, placebo-controlled study 
conducted on patients with interphalangeal joint OA, CS treated patients showed delayed 
progression of OA corroborating its role as SYSADOA (Verbruggen, Goemaere, & Veys, 
1998). In the same study, at an oral CS dosage of 1200 mg/day, no adverse effects were 
seen. This substantiates the safety of CS at doses present in commercially available joint 
health supplements. 
In a  twelve month, randomized, double blind, placebo controlled study conducted by 
Wildi et al., in patients with primary OA of the knee, the CS group showed significantly 
lower cartilage volume loss in as early as six months and fewer bone marrow lesions 
compared to the placebo group after twelve months (Wildi et al., 2011). CS was also 
shown to be effective in management of symptoms in the hand, knee and finger OA 
(Gabay, Medinger-Sadowski, Gascon, Kolo, & Finckh, 2011; Reginster, 2012; Uebelhart, 
Thonar, Delmas, et al., 1998; Verbruggen et al., 1998). CS, in combination with 
glucosamine, was also shown to be effective in management of OA of the knee in 
multiple clinical studies (Das & Hammad, 2000; Povoroznyuk, Grygoryeva, Dzerovych, 
& Karsevskaya, 2010). 
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Despite abundant evidence pointing to the efficacy of CS as a SYSADOA, there are some 
studies in which, the conclusions are not very encouraging. In a 24-week randomized, 
placebo controlled trial with 1000mg/day of CS treatment where symptoms (pain and 
functionality) and biochemical markers of bone, cartilage and synovial metabolism were 
measured, CS was not effective in improving the markers and only slightly better than 
placebo in management of pain (Mazieres, Hucher, Zaim, & Garnero, 2007). Another 
important multi center, double blind, placebo and Celecoxib (a non-steroidal anti-
inflammatory drug) controlled study, the Glucosamine/Chondroitin Arthritis intervention 
Trial (GAIT), that was conducted to evaluate the efficacy and safety of CS and 
glucosamine as a treatment for knee pain from osteoarthritis also revealed that, overall, 
glucosamine or CS alone, or in combination, were not better than placebo in reducing 
knee pain by 20%. But, in sub group of patients with moderate to severe OA of knee, CS 
in combination with glucosamine significantly lowered pain compared to placebo (Clegg 
et al., 2006).   
Interestingly, not only human clinical trials but also a number of animal studies provide 
evidence supporting the efficacy of CS treatment in OA. In horses with degenerative joint 
disease (DJD), CS in combination with glucosamine showed a trend towards the 
improvement in both objective and subjective outcomes, but the lack of a placebo group 
and the small number of animals limited statistical analysis of results (Hanson, Smalley, 
Huff, White, & Hammad, 1997). Orally administered CS was shown to have protective 
effects on chymopapain-induced cartilage damage in rabbits (Uebelhart, Thonar, Zhang, 
& Williams, 1998). Orally administered CS along with glucosamine was shown to be 
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beneficial in alleviating clinical, inflammatory and histological parameters of adjuvant-
induced arthritis in rats (Chou et al., 2005). Long-term oral administration of 
glucosamine and CS reduced the destruction of cartilage and the upregulation of matrix 
metalloproteinase-3 (MMP-3) mRNA in a model of spontaneous osteoarthritis in Harley 
guinea pigs (Taniguchi et al., 2012). 
In spite of numerous clinical trials confirming the efficacy and safety of CS at the 
dosages provided in supplements, questions have been raised regarding shorter durations 
and the lack of important demographic information of participants. According to an 
editorial in the Journal of the American Medical Association (JAMA), these two 
shortcomings of the clinical studies make it difficult to generalize the results of meta-
analysis to individual patients (Towheed & Anastassiades, 2000). Most of the reviews 
and meta-analyses agree on the efficacy of CS in OA but considered the effect to be 
modest  (Bruyere & Reginster, 2007; Huskisson, 2008; Jerosch, 2011; Kelly, 1998; Leeb, 
Schweitzer, Montag, & Smolen, 2000; McAlindon et al., 2000; Richy et al., 2003; Nicola 
Volpi, 2004). However, the conclusions of these meta-analyses were equivocal due to 
variations in methodological quality and efficacy, which made their reliability 
questionable (Black et al., 2009).  
The role of CS as part of  PG molecules is extended to crucial biological functions e.g., 
growth factor signaling, axonal growth and regeneration, neuritogenesis during CNS 
development, morphogenesis and cell division (Sugahara et al., 2003). It is also effective 
in lowering systemic inflammation associated with chronic inflammatory diseases like 
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the cardiovascular diseases and rheumatoid arthritis. Intra-peritoneal injection of CS 
administered to rabbits with atherosclerosis aggravated by induced chronic OA hindered 
progression of atherosclerosis by reducing the serum levels of pro-inflammatory 
cytokines C-reactive protein and IL-6. By altering other inflammatory and histological 
parameters, CS proved to be beneficial in slowing down the progression of 
atherosclerosis in these rabbits (Herrero-Beaumont et al., 2008). In adjuvant induced 
arthritis in a rodent model, administration of CS resulted in significant reduction in 
oxidative stress associated with inflammation. In these animals, 14 day pre-treatment 
with CS was proven to be more effective than administration of CS at the beginning of 
adjuvant induction of arthritis, which highlights the SYSADOA effect of CS (Bauerova 
et al., 2011). 
1.2.3. Bioavailability of CS: 
All the above evidence makes a strong case in favor of CS as a supplement for people 
with OA and for people with rheumatoid arthritis too, considering its systemic anti-
inflammatory activity. As seen from its structure (Figure.1.1), however, CS is actually a 
heterogeneous group of compounds with variable molecular weights and sulfation 
patterns. Despite this structural variation, there is a dearth of research comparing CS 
samples of different molecular weights in terms of bioavailability as well as activity. 
Different studies showed different percentage absorption of CS (A. Adebowale, Du, 
Liang, Leslie, & Eddington, 2002; Barthe et al., 2004; Conte et al., 1991; J. Du, White, & 
Eddington, 2004; C. G. Jackson et al., 2010; N. Volpi, 2010).  
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In rats and dogs, about 10% of the orally administered 14 kDa MW CS was seen to be 
absorbed intact (Palmieri, Conte, Giovannini, Lualdi, & Ronca, 1990). Another study 
conducted in dogs also confirmed the absorption of intact CS (not digested into its 
component disaccharides) as well as CS‘s low molecular weight derivatives (A. 
Adebowale et al., 2002). In a study conducted in horses, both 8 kDa CS and 16.9 kDa 
orally administered CS were absorbed (J. Du et al., 2004). An in vitro study conducted 
using rat gut sacs also provided evidence of CS being absorbed in the GI tract (Barthe et 
al., 2004). 
In humans, at an oral dose of 3 g, about 13% of CS with a mean molecular weight of  16 
kDa appeared to be bioavailable (Conte et al., 1991). When partially depolymerized shark 
CS of mean molecular weight (MMW) 7.5 kDa was administered to human subjects at a 
dosage of 1.2 grams, about 10% was absorbed intact (G. Ronca & Conte, 1993). 
Although, in a study conducted on patients with symptomatic knee pain by Jackson et al., 
no significant increase in plasma concentration of CS was reported when single dose CS 
was administered orally, this finding has been attributed to the detection limits of 
analytical methods, fluorophore-associated carbohydrate electrophoresis (FACE) and 
superose 6 chromatography used  to measure the plasma concentrations of CS (C. G. 
Jackson et al., 2010; N. Volpi, 2010).  
In a group of healthy male volunteers, oral administration of  4 g of CS with a mean 
molecular weight  24 kDa and of bovine origin, over a time period of 48 hrs, resulted in 
significant increase in plasma CS levels (more than 200%) detected qualitatively as well 
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as quantitatively by agarose-gel electrophoresis (N. Volpi, 2002). When ichthyic origin 
CS of MMW 44 kDa was orally administered to healthy male volunteers at the same 
dosage as above (4 g single dosage), it only showed a moderate increase (120%) in 
plasma CS concentrations (N. Volpi, 2003). In a study conducted in horses, 8 kDa CS 
showed higher bioavailability compared to CS of molecular weight 16.9 kDa (32% as 
opposed to 22% respectively), but this difference is found to be statistically insignificant, 
probably due to the small number of animals involved in the study (J. Du et al., 2004).  
All of this evidence supports the idea of high molecular weight CS being less 
bioavailable compared to the low molecular weight CS.  
Although speculations have been made regarding the correlation between MW of CS 
sources and their bio availability, at present, no such targeted studies have been 
conducted either in vitro or in vivo. Hence, the focus of this study is to investigate the 
relationship of MW of CS with its in vitro absorption and anti-inflammatory activity. The 
research has been divided into three major objectives- 
1. To determine the molecular weights and disaccharide composition of CS samples 
used in this study. 
2. To determine the in vitro absorption of CS samples and its correlation with 
molecular weight. 
3. To determine the in vitro anti-inflammatory activity of CS samples and its 
correlation with molecular weight. 
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CHAPTER 2 
DETERMINATION OF MOLECULAR WEIGHTS AND DISACCHARIDE 
COMPOSITIONS OF CHONDROITIN SULFATE (CS) SAMPLES 
CS is a highly heterogeneous molecule due to the variations in its molecular weight and 
sulfation patterns. Molecular weights and disaccharide compositions of CS from different 
animal sources were listed in Table 1.1 (Mucci et al., 2000). For this study, a total of 8 
CS samples of unknown molecular weights were obtained from 4 different raw material 
suppliers. For confidentiality purposes, code names were assigned to the samples and 
their suppliers. Table 2.1 provides these assigned names, sources and suppliers of CS 
samples.  
Table 2.1: Assigned names, sources, and suppliers of CS samples used 
Name of the sample Source Supplier 
Sample A Synthetic Supplier 1 
Sample B Synthetic Supplier 1 
Sample C Bovine cartilage Supplier 2 
Sample D Bovine cartilage Supplier 3 
Sample E Porcine Supplier 4 
Sample F Bovine trachea Supplier 2 
Sample G Synthetic Supplier 1 
Sample H Synthetic Supplier 1 
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Samples A, B, G and H were provided by the same independent supplier, supplier 1. 
Samples D and E were provided by independent CS raw material suppliers 3 and 4 
respectively. Samples C and F were purchased from Sigma-Aldrich (Sample C- Catalog # 
C6737 and Sample F- Catalog # C9819). 
2.1. Determination of Molecular weight (MW): 
Analytical methods such as fluorophore assisted carbohydrate electrophoresis (FACE) 
(Buzzega, Maccari, & Volpi, 2010), high performance size exclusion chromatography 
(HPSEC) (Mucci et al., 2000; N. Volpi & Bolognani, 1993; N. Volpi et al., 1998) and 
agarose gel-electrophoresis were utilized by researchers in the past to determine MW of 
CS.  HPSEC method slightly modified from Volpi and Bolognani (1993) was used as the 
analytical method to determine the MWs of CS samples used in this study. Known 
molecular weight CS samples were used as standards. 
2.1.1. Material and methods: 
CS standards of known MW were provided by an independent supplier, supplier 1. 
Briefly, two Agilent Bio SEC-3 (150 x 7.8 mm) columns with pore sizes 150 Å and 100 
Å (Agilent, Part # 5190-2507 and # 5190-2502) were connected in tandem.  80% buffer 
(30 mM Disodium hydrogen phosphate, 30 mM Sodium sulfate, pH 7) and 20% ethanol 
was used as mobile phase at a flow rate of 1.0 ml/min and run time of 15 minutes. 5 µl 
injection volumes of standards or samples were injected and chromatograms were 
recorded at 205 nm using a photo diode array (PDA) detector (Waters # 2998 PDA 
detector). A standard curve was plotted using retention times of standards and their 
corresponding molecular weights. The standard curve was then used to determine 
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molecular weights of CS samples whose retention times were known. The detailed 
protocol is attached as Appendix 1. 
2.1.2. Results:  
A CS standard curve was plotted as outlined in the materials and methods section and 
Appendix 1. The curve best fitting to the data was a third degree polynomial. Figure 2.1 
shows the equation of the standard curve (R
2
 = 0.99) that was used to calculate molecular 
weights of CS samples. 
 
Figure 2.1: CS standard curve: Y- axis= log (molecular weight in daltons), X-axis= 
(retention volume of internal standard / retention volume of CS standard) 
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Table 2.2: Calculated molecular weights of CS samples 
 
Molecular weights of CS samples were calculated using the standard curve equation 
shown in Figure 2.1. Table 2.2 presents the calculated molecular weights.  Samples E and 
F were of same molecular weight (31 kDa). Same is the case with samples G and H (35 
kDa). Molecular weights of samples A (7 kDa) and B (8 kDa) as well as C (21 kDa) and 
D (20 kDa) differ by only one kDa from each other.  
2.2 Determination of disaccharide composition: 
CS represents a highly heterogeneous group of unbranched polysaccharides characterized 
by alternating disaccharide units of N-acetyl galactosamine and glucuronic acid as seen in 
Figure 1.2. Heterogeneity of CS is partly due to  the presence of sulfate groups in 
different amounts and  in various positions (2 and 3 of uronic acid, and 4 and 6 of N-
CS sample MW in kDa 
Sample A 7 
Sample B 8 
Sample C 21 
Sample D 20 
Sample E 31 
Sample F 31 
Sample G 35 
Sample H 35 
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acetyl-galactosamine residues) (Nicola Volpi, 2004). Chondroitinase ABC and 
chondroitinase AC II have been used to hydrolyze CS into its component disaccharides. 
The hydrolysis was then followed by quantitative determination of those disaccharides 
using capillary electrophoresis (Bayliss et al., 1999; Karamanos, Axelsson, Vanky, 
Tzanakakis, & Hjerpe, 1995; Malavaki et al., 2008; N. Volpi, 2004), strong anion 
exchange –HPLC (N. Volpi, 2003), precolumn derivatization and fluorescence detection 
(J. P. Du & Eddington, 2002),  and HPLC with UV detection (J.-S. Sim et al., 2007). 
Chondroitinase ABC hydrolyzes both chondroitin sulfate and dermatan sulfate 
(sometimes referred to as chondroitin sulfate B) whereas chondroitinase AC II is specific 
for CS(Ji, Roman, Zhou, & Hildreth, 2007). 
Disaccharide compositions of CS samples used in this study were determined by 
enzymatic hydrolysis of CS samples by chondroitinase AC II followed by ion-pairing 
reversed-phase liquid chromatography (LC) – UV method developed and validated by Ji 
et al (Ji et al., 2007).  
2.2.1. Materials and methods 
Briefly, CS samples were incubated with chondroitinase AC II, an enzyme specific to 
chondroitin sulfate for 3 hours at 37 
o
C to hydrolyze CS into its component disaccharides. 
Disaccharides were then separated and quantified by ion-pairing liquid chromatography 
with ultraviolet detection at 240 nm. For detailed protocol, refer to Appendix 2. 
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2.2.2. Results: 
Percentage disaccharides present in CS samples were determined as outlined in Appendix 
2. Table 2.3 presents the disaccharide composition of CS samples used in this study. 
Percentage disaccharide compositions were reported as % mean ± standard error.  
Table 2.3: Disaccharide composition of CS samples (n=4) 
Sample % ΔDi-0S (Mean±SE) %ΔDi-4S (Mean±SE) %ΔDi-6S (Mean ±SE) 
A 6.91 ± 0.4 66.61 ± 3.7 26.49 ± 3.2 
B 7.36 ± 0.7 00.00 ± 0.0 92.64 ± 0.7 
C 9.06 ± 1.5 64.21 ± 2.0 26.73 ± 0.5 
D 9.44 ± 1.7 63.73 ± 2.3 26.83 ± 0.6 
E 10.14 ± 1.9 68.84 ± 3.3 21.01 ± 1.3 
F 8.56 ± 1.4 75.58 ± 2.8 15.87 ± 1.3 
G 11.11 ± 1.7 00.00 ± 0.0 88.89 ± 1.7 
H 10.50 ± 1.5 00.00 ± 0.0 89.50 ± 1.6 
Synthetic CS samples B, G and H had no measurable 4-sulfated disaccharide and had 
approximately 90% of 6-sulfated disaccharide. Sample F (from bovine trachea) had the 
highest percentage of 4-sulfated disaccharide. Percentage of 4 – sulfated disaccharide 
varied little between samples A, C, D and E. Samples C and D were from bovine 
cartilage, sample E was from porcine source and A was synthetic. 
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Objective 1 was completed by characterizing the CS samples used in this study in terms 
of their molecular weights and disaccharide compositions. In later chapters, the 
relationship between the above mentioned parameters and in vitro absorption and anti-
inflammatory characteristics of CS samples were determined. 
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CHAPTER 3 
DETERMINATION OF IN VITRO ABSORPTION OF CS SAMPLES  
AND ITS RELATIONSHIP WITH MOLECULAR WEIGHT 
3.1 Introduction 
The variation in molecular weights and sulfation patterns make CS a heterogeneous 
molecule. Although speculations have been made regarding differences in the bio-
availability of CS (A. O. Adebowale, Cox, Liang, & Eddington, 2000; Cho et al., 2004; J. 
Du et al., 2004; Palmieri et al., 1990; N. Volpi, 2003), due to its structural variations, no 
detailed study has yet been conducted to investigate the effects of these variations on 
absorption. Even though clinical trials or animal studies may provide a deeper insight into 
the molecular weight: bioavailability relationship of CS, the tedious and expensive nature 
of such studies demands a preliminary screening tool which can identify 
candidates/samples that might have higher bioavailability and could potentially be 
included in a clinical trial. To this end, in vitro models of intestinal absorption can 
provide an alternative to in vivo studies. 
Currently, in-vitro models are being used extensively by researchers to understand 
mechanisms of absorption of nutrients and transportation of drugs across the intestinal 
lining. As reviewed by Le Ferrec et al., (Le Ferrec et al., 2001) in a report on ‗In vitro 
models of the intestinal barrier‘, mechanisms of transportation across the intestinal barrier 
include transcellular transportation (carrier mediated or active transportation, endocytosis 
and pinocytosis), paracellular transportation or passive diffusion through the tight 
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junctions (Figure 3.1). Mode of transportation depends on the physicochemical properties 
of the compound such as structure, molecular weight or size, charge distribution and 
hydrophobicity (Le Ferrec et al., 2001).  
As identified in the report and recommendations of European Center for the Validation of 
Alternative Methods (ECVAM) some examples of in vitro models of intestinal 
absorption include- (i) everted gut sac of the rat small intestine, (ii) isolated and perfused 
intestinal segments, (iii) Ussing chambers, (iv) cell models, etc. Cell models include 
isolated human intestinal epithelial cells, small-intestine cell lines from fetal and neonatal 
rats, non-intestinal cell systems like Madin Darby canine kidney (MDCK) cells, and 
human adenocarcenoma cell lines like HT-29 and Caco-2 (Le Ferrec et al., 2001). 
 
Figure 3.1: Mechanisms of transportation across small intestinal epithelial cells. 
Caco-2 cells are isolated from a primary colonic tumor. When cultured under standard 
cell culture conditions, they spontaneously differentiate into polarized enterocytes 
characterized by apical and basolateral sides, presence of tight junctions (Figure 3.2) and 
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expression of most of the small intestinal brush border enzymes and transporters (Table 
3.1). 
               
Figure 3.2: (Left) Confocal analysis of occludin staining (green) revealing tight junctions 
status in the CacoReady™ cell barrier (made available by ADMEcell, Emeryville, CA). 
(Right) Pictorial representation of a well from CacoReady™ plate.  
Note: CacoReady™ is a trademark of ADVANCELL. ADMEcell is a licensed distributor 
of CacoReady™ 24-well kit by ADVANCELL. 
Similar to intestinal transportation/absorption of nutrients, Caco-2 cell monolayer also 
facilitates transportation by transcellular and paracellular pathways. In a review article 
comparing drug transport in Caco-2 monolayers with intestinal drug transport in vivo, 
Artrusson et al. concluded that Caco-2 monolayers can be used to predict drug transport 
by different pathways across the intestinal epithelium. It was also reported that the best 
correlation to the in vivo situation was obtained for drugs that are absorbed by the 
paracellular transportation mechanism (Artursson, Palm, & Luthman, 2001). 
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Table 3.1: Characteristics of parental Caco-2 cells*  
Origin Human colorectal adenocarcinoma 
Differentiation 14-21 days after confluence in standard 
cell culture medium 
Morphology Polarised cell monolayer with tight 
junctions and apical brush border 
Electrical parameters High electrical resistance 
Digestive enzymes Membranous peptidases and 
disaccharidases of the small intestine 
Receptors/Transporters Permeability glycoprotein (p-
glycoprotein); multidrug resistant 
associated protein;  glucose transporters 
(GLUT)- GLUT1, GLUT2, GLUT3, 
GLUT5; Sodium-glucose transporter 
(SGLT1); vitamin B12;  vitamin D3 . 
*Adapted from (Le Ferrec et al., 2001) 
Paracellular transportation was identified as the primary mechanism of transportation of 
CS disaccharides, and low molecular weight and intact CS (Jin et al., 2010; J. S. Sim et 
al., 2005). Hence, the Caco-2 monolayer model was chosen for this study to examine the 
relationship of absorption of CS with its molecular weight and/or sulfation patterns.  
 
28 
 
3.2. Materials and methods: 
According to the protocol provided by ADMEcell, CacoReady™ is a new ready-to-use 
concept for in vitro intestinal absorption evaluation. This kit provided a 21-cell barrier in 
integrated HTS Transwell
®
 -24 (A registered trademark of Corning Lifesciences) with an 
exclusive and proprietary shipping medium that is stable at room temperature. The kit of 
differentiated Caco-2 cell barriers was shipped on day 13 of differentiation and provided 
14- day polarized cultures of Caco-2 cells on polycarbonate micro-porous filters in HTS 
Transwell
®
 -24 plates (6.5 mm diameter, 0.33 cm
2
 area and 0.4 μm pore diameter).  
Plate receipt and preparation: 
1. As per the suggestion of supplier, all permeability experiments were performed on 
Mondays after the CacoReady™ kits were received. Exactly two weeks (14 days) 
prior to shipping the Caco-2 cells were plated in the CacoReady™ plates on a 
Monday. Between days 14- 21, Caco-2 cells differentiate and become confluent to 
form a polarized monolayer, with tight junctions and apical brush border, 
morphologically resembling enterocytes. The Monday after receipt of 
CacoReady™ plates (day 21) is ideal for performing permeability experiments. 
2. The CacoReady™ plates were received on day 18, Friday before permeability 
experiments.  Upon receipt, the plates were unwrapped and inspected for leakages 
and then placed in a biosafety cabinet (BSC) (Labconco, Kansas city, MO. 
Catalog # 3430009) at room temperature until the time for changing the shipping 
medium. 
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3. Shipping medium in the plates was changed following a 4 hr incubation in a 37 oC 
and 5% CO2 incubator (Symphony
TM
 Forced Air, VWR) which allowed transport 
media to liquefy completely.  
4. Caco-2 media was prepared according to the ADMECell protocol. Briefly, 50 ml 
of fetal bovine serum (FBS) (Invitrogen, Catalog # 26140), 5 ml of 200 mM L-
glutamine (Invitrogen, Catalog # 25030) and 5 ml of Penicillin/Streptomycin 
(Invitrogen, Catalog # 15150-148) were added to 440 ml of Dulbecco‘s modified 
eagle medium (DMEM) (Invitrogen, Catalog # 10567). Prepared Caco-2 media 
was labeled and stored at 2-8 
o
C and warmed to 37 
o
C prior to use. 
5.  After 4 hrs incubation, the CacoReady™ plates were placed in the BSC and a 
new Costar 24 well plate (Costar 3526) was placed next to the CacoReady™ 
plates. 
6.  Lids of the new Costar plate and the CacoReady™ plate were removed and 
placed side by side facing upwards, oriented in the same direction. The apical 
plate from the CacoReady™ plate was gently lifted and placed on top of the new 
plate to get access to the basal wells of the CacoReady™ plates.  
7. The transport media in the basal wells of CacoReady™ plate was aspirated using 
an alcohol sterilized aspirator. Then, the media from apical wells of CacoReady™ 
plate placed on new plate was also aspirated. A manifold (Drummond, Catalog # 
3-000-097) was used to aspirate media from the apical wells to avoid accidental 
damage to the cell monolayer. The manifold tips were positioned against the well 
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walls and media was aspirated for 5-7 seconds. By default, 70 µl of media 
remained in each well after aspiration. 
8. Caco-2 media was added to apical wells (230 μl) and basal wells (750 μl). The 
apical plate with media was then returned to the top of the basal CacoReady™ 
plate with media and covered with its lid. This plate was then incubated at 37 
o
C, 
5% CO2 until the day of permeability experiments (Monday). 
Preparation of samples: 
1. Final concentrations of 30 mg/ml CS working samples were prepared by 
dissolving 150 mg of each CS sample in 50 ml sterile 1 X Hank‘s balanced salt 
solution (HBSS) transport buffer. HBSS transport buffer had a composition of 1 
X Hank‘s balanced salt solution (HBSS) (Lonza, Catalog #b04-315Q) with 1.1 
mM MgCl2. 6H2O (Amresco, Catalog # E525) and 1.3 M CaCl2. 2H2O (Amresco, 
Catalog # E506).  
2. CS is water soluble, the samples dissolved completely in transport buffer. The 
samples were then aliquoted and stored at 2-8 
o
C until the day of permeability 
study.  
3. 20 μM propranolol hydrochloride (Sigma, Catalog # P0884) stock solution was 
prepared and serial dilutions were performed to prepare a set of 5 standards 
ranging between 0 μM – 20 μM. The same stock solution was also used to 
prepare 10 μM working solution of propranolol hydrochloride to be used a high 
permeability control.  
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4. Stock, standards, and working solutions of sodium Fluorescein (Sigma, Catalog # 
46960) were prepared in a method similar to that of propranolol hydrochloride. 
Sodium fluorescein was used as a low permeability control. 
5. A 200 μM Lucifer yellow CH dilithium salt (Sigma, Catalog # L0259) stock 
solution was prepared and serial dilutions were performed to prepare a set of 5 
standards (conc. 0 μM- 200 μM). A working sample of 100 μM conc. was also 
prepared from the stock. Lucifer yellow was used to test integrity of the Caco-2 
cell monolayer. 
Measurement of Transepithelial Electrical Resistance (TEER):  
1. On the day of permeability experiments (Monday) TEER measurement was 
performed using an Epithelial Volt-Ohm meter (EVOM) (World precision 
instruments, Catalog # EVOM2) on the CacoReady™ plate prior to any further 
processing. According to the supplier, plates with TEER < 1000 Ohm. cm
2
 were 
considered unacceptable on which to perform permeability assays. All the plates 
met the required criteria. 
2. The electrodes (probe) (World precision instruments, Catalog # STX 100) were 
sterilized by submerging the probe in 70% ethanol for 30 minutes, then 
equilibrated by submerging for another 30 minutes in Caco-2 media at room 
temperature. 
3.  While equilibrating the probe, the CacoReady™ plate was also removed from the 
incubator and placed in the BSC to allow it to reach room temperature. TEER 
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measurements were performed at room temperature according to CacoReady™ 
supplier‘s instructions.  
4. Briefly, the shorter electrode of the probe was slightly submerged inside the 
culture medium of the apical (upper) compartment and the longer arm was placed 
through the lateral hole of the CacoReady™ plate to submerge it in the medium of 
the basal (lower) compartment. Care was taken not to touch the cell monolayer 
with the electrode.  
5. EVOM measures the resistance in Ohms. TEER was calculated using Equation 
3.1.  
                                                                               ……………Equation 3.1 
Where, R is resistance measured by EVOM in Ohms 
A is the area of cell monolayer, which is 0.33 cm
2
 
TEER > 1000 Ohm cm
2
 was considered acceptable for permeability assay. 
Apical to basal permeability protocol: 
 As mentioned earlier, all permeability assays were performed on a Monday. Working 
solutions of test compounds were prepared as outlined in the sample preparation section. 
The CS samples, blank transport buffer, high permeability and low permeability controls, 
and Lucifer yellow were all warmed to 37 
o
C prior to the experiments. The following 
steps were followed: 
TEER = (R x A) Ω. cm2 
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1. A sterile cell culture medium container placed in the BSC was filled with 50 ml of 
transport buffer at 37 
o
C, kept warm in a water bath (Lab companion, Model BS-
21).  
2. The CacoReady™ plate and a new Costar basal plate were kept next to each other 
in same direction. The lids of both plates were removed and placed next to the 
plates.  
3. The apical (upper) section of the CacoReady™ plate was gently lifted and placed 
on the new Costar basal plate.  
4.  The medium from the basal compartment of CacoReady™ plate was aspirated 
and discarded using an aspirator with a sterile tip.  
5. The basal compartment of CacoReady™ plate was washed with 750 ul of transfer 
buffer per well. Following aspiration of the transport buffer wash, 750 μl of 
transport buffer was aliquoted per well again.  
6. Cell culture medium from apical compartment wells was aspirated and discarded 
using a manifold. The apical wells were then gently washed by filling, aspirating 
and discarding 300 μl of transport buffer per well using a manifold.  
7. As aspirating with a manifold leaves 70 μl of transport buffer in each well, the 
volume of apical samples was adjusted for a 300 μl total volume. Therefore, 230 
μl each of samples, controls and blank transport buffer were filled in the apical 
wells to make a total apical volume of 300 μl according to the plate design (Figure 
3.3). 
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Figure 3.3: Caco-2 plate design. Samples are denoted by letters A-H. Bln=blank, 
Pr=propranolol hydrochloride, Fl=sodium fluorescein and LY=Lucifer yellow. 
8. The apical section with samples was then gently lifted from the Costar basal plate 
and placed back on the CacoReady™ plate with transport buffer filled wells. The 
Costar plate was discarded after this. 
9. CacoReady™ plate was then placed in the incubator at 37 oC, 5% CO2 for 2 
hours. 
10. After 2 hours, the CacoReady™ plate was removed from the incubator and placed 
in the BSC. A new Costar basal plate was placed next to it and lids of both plates 
were removed. 
11. The apical section of CacoReady™ plate was gently lifted from the CacoReady 
plate and placed on top of the new Costar basal plate. 
12. Samples from apical wells (now kept on top of the Costar plate) and basal wells 
of the CacoReady™ plate were then collected separately into 1 ml Eppendorf 
tubes, labeled and stored at -20 
o
C until analysis. 
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13. Quantitative analysis of CS in apical and basal samples was done by enzyme 
hydrolysis and RP-HPLC outlined in Appendix 2.  
14. Apical and basal concentrations of propranolol, sodium fluorescein and lucifer 
yellow were analyzed by Fluorescence spectrophotometry (SpectraMax M2e, 
Molecular Devices, LLC., Sunnyvale, CA). Briefly, standard curves were 
obtained for each compound by measuring their OD values of respective 
standards of known concentrations. OD values for propranolol (sodium 
fluorescein and lucifer yellow) were measured at absorption wavelength (λa) of 
280 nm (460 and430 nm) and emission wavelength (λe) of 320 nm (515 and 540 
nm). Standard curves were plotted with concentration of sample (propranolol or 
fluorescein or Lucifer yellow) on y-axis against their OD values on x-axis. The 
standard curves equations were then used to calculate concentrations of 
propranolol, sodium fluorescein and lucifer yellow samples from the permeability 
experiment. 
15. Once the concentrations of all the apical and basal samples were determined, 
coefficients of effective permeability Peff (cm.s
-1
) were calculated using the 
following relationships: 
                                                                                                  ………Equation 3.2 
Where VR = Volume of transport buffer in basal or receiving compartment (cm
3
) 
A= area available for absorption (surface area of the cell monolayer = 0.33 cm
2
) 
C0= Initial concentration of the sample in apical compartment (mg.mL
-1
) 
Peff = VR. (dC/dT) / A. C0 
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(dC/dT ) = Change in concentration of sample with respect to time.  
In this case, dC/dT was calculated as (Cf- Ci)/ΔT. Where Cf  and Ci were initial 
and final concentrations of sample in the basal compartment. And, ΔT was 
duration of permeability which was 2 hours (7200 seconds).  
16. The coefficients of effective permeability of all 8 samples as well as control 
samples (propranolol hydrochloride and sodium fluorescein) were determined 
using equation 2.1. Values were based on the means of two replicates per plate in 
two plates (a total of four replicates).  
17. Analysis of variance (ANOVA) test was used (JMP Pro 10) to test for differences 
between samples at (p-value ≤ 0.05) as well as inter plate and intra plate 
variability.  
18. A one way student t-test was performed to compare sample means. Differences 
were considered significant at p-value ≤ 0.05. 
3.3 Results:  
Absorption of CS samples was expressed as coefficients of effective permeability (Peff) as 
outlined in methods.  The Peff values for the samples A through H, propranolol 
hydrochloride (high permeability control), sodium fluorescein (low permeability control) 
and lucifer yellow (indicator of cell monolayer integrity, not shown in figure) are 
presented in Figure 3.4. The Peff values of lucifer yellow and sodium fluorescein were 
both zero. This, in addition to the TEER value >1000 Ω cm2, guarantees the integrity of 
Caco-2 monolayers used in this study.  
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Figure 3.4: Coefficients of effective permeability (Peff) for CS samples and control 
samples. Mean Peff value for each sample is represented on top of column for each 
sample. 
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Figure 3.5: Trends of MW of CS samples and their absorption in terms of Peff. Molecular 
weights (in kDa) and of Peff (in cm.s
-1
) are represented on top of each column for 
respective samples. 
As seen from Fig. 3.5, which shows the variation in coefficient of effective permeability 
of samples with the MW, no correlation is apparent concurring with the coefficient of 
effective permeability and molecular weight relationship presented in Fig. 3.4. Table 3.1 
presents ranking of CS samples in descending order of their Peff values. Samples D and E 
had relatively low permeability coefficients and were significantly different from rest of 
the samples.  Samples A, C, F and G had permeability coefficients ranging between 10- 
16 x 10
-6 
cm.s
-1
, but did not significantly differ from each other. Samples F, G and H 
whose permeability coefficients were between 15- 21 x 10
-6
 cm.s
-1
 were also not 
significantly different from each other (p>0.05).  Importantly, the Peff of sample B 
appeared to be significantly higher than rest of the samples except for sample H. Of the 
11.63 
24.19 
10.46 
0.36 
3.07 
16.54 15.04 
21.35 
7 8 
21 20 
31 31 
35 35 
0.00
10.00
20.00
30.00
40.00
A B C D E F G H
CS Samples 
P eff and molecular weights of CS samples  
P eff X 10^-6 cm/s Molecular weight in kilo daltons (kDa)
39 
 
four synthesized samples (A, B, G and H), sample A had a significantly lower 
permeability than the others. 
Table 3.2: Ranking of CS samples based on coefficient of permeability  
 
Sample Mean (P eff x 10
-6
 cm. s
-1
 ) 
Sample B 24.19
(α)
 
Sample H 21.34
(α)(β) 
Sample F 16.53
(β)(γ) 
Sample G 15.04
(β)(γ) 
Sample A 11.63
(γ) 
Sample C 10.46
(γ) 
Sample E 3.06
(δ) 
Sample D 0.35
(δ) 
 
Note: Levels not connected by same Greek letter are significantly different (P<0.05) 
Bivariate fits were obtained to determine any correlations between absorption and 
molecular weight, percentage 6-sulfated fraction and, total sulfated fraction of CS in 
samples. Pearson correlation factor ‗R2‘ was used to assess the above mentioned 
relationships. R
2
 between and 0.5 to 1.0 were considered high.  
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Relation between coefficient of effective permeability and molecular weight: 
 
Figure 3.6: Bivariate fit of Peff x 10
-6
 (cm.s
-1
) and molecular weight (kDa) 
As seen in Fig. 3.6, there appears to be no correlation (R
2
<0.5, P>0.05) between the 
permeability coefficient and molecular weight of CS samples within the molecular 
weight range of samples used in this study (7 kDa to 35 kDa).   
Relation between coefficient of effective permeability and percentage of 6-sulfated 
disaccharide in CS sample: 
The bivariate fit of Peff and % ΔDi- 6S in CS sample resulted in R-square value of 0.5, P 
= 0.0477 which revealed that these two parameters were correlated, albeit weakly. 
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Figure 3.7: Bivariate fit of Peff x 10
-6
 (cm.s
-1
) and % ΔDi-6S 
As seen in Fig. 3.7, except for sample F, all the samples with % 6 S–disaccharide < 30% 
had a Peff  value < 15 x 10
-6
 cm.s
-1
. Among synthetic CS samples (A, B, G and H), only 
sample A had percentage 6-sulfated disaccharide less than 30% and incidentally, had the 
lowest Peff value. Samples B and H that are higher in 6-sulfated disaccharides also have 
higher permeability coefficients. 
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Relation between coefficient of effective permeability and total percentage of 
disaccharides in CS sample: 
The bivariate fit of Peff and percentage of total sulfated disaccharides (sum of % 4S and 
%6S, reminder unsulfated) in CS samples resulted in an R
2 
value of 0.03 strongly 
suggested that no correlation existed between percentage of total sulfated disaccharides 
(also termed as amount of sulfation) and coefficient of effective permeability (absorption) 
of CS samples tested. However, as evident from Fig. 3.8, percentage of total sulfated 
disaccharides varied little between the samples (range 89%- 93%). Samples with wider 
range of variable sulfated disaccharide percentages are needed to verify this observation.  
 
Figure 3.8: Bivariate fit of Peff x 10
-6
 (cm.s
-1
) and total % of sulfated disaccharides 
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CHAPTER 4 
DETERMINATION OF IN VITRO ANTI-INFLAMMATORY ACTIVITY AND 
ITS RELATIONSHIP WITH MOLECULAR WEIGHT OF CS SAMPLES 
4.1 Introduction 
Inflammation plays a major role in the progression of osteoarthritis (OA) (Bonnet & 
Walsh, 2005; Brooks, 2003; Dieppe, 1978; Ehrlich, 1975; Peyron, 1981). Synovitis (the 
inflammation of synovial membranes) is often present at the site of the joint affected by 
OA. Inflammation is known to be more common in advanced stages of OA rather than 
the early stages (D'Agostino et al., 2005). Synovial fluid from patients with OA often 
exhibits increased volume, reduced viscosity, and elevated white blood cells which are 
predominantly mononuclear (monocytes and lymphocytes) (Altman & Gray, 1985).  
Cytokines are cell-produced chemical signals that play a crucial role in cell-cell 
interactions. They are often classified as catabolic, anti-catabolic, modulatory or anabolic 
with respect to their role in regulation of chondrocyte function. In the case of OA, 
catabolic cytokines promote degradation of cartilage; while anti-catabolic cytokines 
inhibit or antagonize the activity of catabolic cytokines. Anabolic cytokines act as growth 
and differentiating factors on chondrocytes and increase their activity. Modulatory 
cytokines are the ones that regulate the activity of other cytokines. IL-6 is a modulatory 
cytokine whereas TNF-α and IL-1β are catabolic cytokines (S. R. Goldring & Goldring, 
2004). 
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C-reactive protein is an acute phase protein and is a marker of systemic inflammation. In 
a clinical study comparing rapid versus slow progressive hip arthritis, the serum C-
reactive protein (CRP) levels in a rapid progressive hip arthritis group were reported to be 
significantly higher (over 2 times) than individuals having the slow progressive form 
(Conrozier et al., 1998). In another clinical study of subjects with early knee OA, slight 
but definite, increased serum CRP levels were reported in subjects whose disease 
progressed over the next four years suggesting that low grade inflammation may be a 
significant aspect of early OA and could be a target for pharmacological intervention 
(Spector et al., 1997). 
These results are supported by several review articles which discuss the role of cytokines 
in OA pathophysiology and emphasize the importance of pro-inflammatory (catabolic) 
cytokines in the initiation and progression of the disease (Fernandes et al., 2002; M. B. 
Goldring, 2000; Mary B. Goldring & Otero, 2011; Hedbom & Hauselmann, 2002). In 
synovial tissue obtained from patients with early and late OA, an over expression of pro-
inflammatory cytokines TNF-α and IL-1β were seen in early OA, compared with late 
OA. Increased monocyte infiltration was also reported to be present in early OA (Benito 
et al., 2005). Macrophages derived from these monocytes are a source of inflammatory 
cytokines. Nitric oxide (NO) is another signaling molecule that plays a role in the 
pathogenesis of inflammation. NO is synthesized when arginine is converted to citrulline. 
In a review by Abramson on the role of NO and reactive nitrogen species (RNOS) in OA, 
it had been suggested that NO may not only act as an inflammatory mediator but also 
might have protective functions in individual cell types (tendons and osteoblasts) in 
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arthritic joints. It was also reported that not all chondrocytes produce equivalent amounts 
of NO (Steven B. Abramson, 2008).  
Based on an intensive literature search for the role of inflammation in OA and the 
associated specific inflammatory markers, four inflammatory markers (TNF-α, IL-1β, IL-
6 and NO) were identified as candidate biomarkers for assessing the anti-inflammatory 
(AI) activity of the CS samples in our studies. (S. B. Abramson, 2004; Steven B. 
Abramson, 2008; Pelletier et al., 1991; Scanzello et al., 2008; Shinmei, Masuda, Kikuchi, 
& Shimomura, 1989; Shinmei & Nemoto, 1996; Smith, Triantafillou, Parker, Youssef, & 
Coleman, 1997; Westacott & Sharif, 1996). Compounds that can regulate expression of 
these inflammatory markers may be able to perhaps delay and/or attenuate the 
progression of OA.  
CS is currently being used as a symptomatic slow acting drug for osteoarthritis 
(SYSADOA) and had been shown to be effective in management of pain and 
improvement in functionality of joints in several animal studies and clinical studies. 
Understanding the mechanisms of action of CS might provide insight into the improved 
efficacy if this compound as a remediation for OA.  Our study was designed to examine 
the effect of CS on the aforementioned inflammatory biomarkers in vitro.  
Murine macrophage cell lines (RAW 264.7) were chosen as the model for the AI activity 
experiments as macrophages are known to play an important role in inflammatory 
response (Bondeson et al., 2010; Bondeson, Wainwright, Lauder, Amos, & Hughes, 
2006). When stimulated by bacterial lipopolysaccharide (LPS), RAW 264.7 cells were 
46 
 
reported to express various cytokines, reactive oxygen and nitrogen species, growth 
factors etc., thus supporting this cell line‘s use as an appropriate in vitro model for 
assessing AI activity of various compounds (Achoui et al., 2010; Chun et al., 2007; Gao 
et al., 2012; Jung & Sung, 2004; Kang et al., 2011; Kim, Cheon, Kim, Kim, & Kim, 
1999; Moro et al., 2012; Oh, Cho, Jeong, et al., 2012; Oh, Cho, Oh, et al., 2012; Suh et 
al., 1998; Terra et al., 2007; Tuntipopipat, Muangnoi, & Failla, 2009; Yoon et al., 2009; 
Zong et al., 2012).  
One of the objectives of this research project was to determine the AI activity of 8 
different CS samples with variable MW and sulfation patterns and correlate them, to the 
AI activity. AI activity was quantified by measuring the levels of the respective 
inflammatory markers expressed in the presence of each CS sample when the cells were 
stimulated by the powerful pro-inflammatory mediator, bacterial LPS. Two different 
concentrations (low and high) of each CS sample were used to verify if there existed an 
AI activity dose response.  
4.2 Materials and methods: 
Briefly, RAW 264.7 cells were cultured under standard cell culture conditions. Viable 
cells were then plated and incubated at 37 
o
C and 5% CO2 prior to addition of CS 
samples to facilitate adhesion of cells to the wells. CS samples were then added to the 
wells and incubated at 37 
o
C and 5% CO2 one more hour before adding LPS. This one 
hour incubation with CS samples was done to facilitate absorption of CS by the cells 
before addition of LPS. Once the cell supernatant was removed after the experiment, 
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MTS assay was performed on the cells in the wells. This was done to ensure that the 
concentrations used in this protocol, neither CS samples not LPS were toxic (causing cell 
death) to the cells. The detailed protocol for the experiment is described below. 
Culturing of RAW 264.7 cells (Eton Bioscience, Inc. San Diego, CA. Catalog # 
2800080012):  
1. RAW 264.7 cells were thawed rapidly (for approximately 2 minutes) in a water 
bath at 37
 o
C by gently agitating the vial. After thawing was complete, the surface 
of the vial was chemically sterilized by a solution of 70% ethanol. All operations 
from this point were carried out under strict aseptic conditions in a laminar flow 
biosafety level -2 (BSL-2) hood. 
2. Contents of the vial were then transferred into a centrifuge tube containing 9.0 ml 
complete culture medium (DMEM + 10% FBS + 2mM L-glutamine) and 
centrifuged at 2795 g for 5 minutes.  
3. The cell pellet was then resuspended in 10 ml of complete culture medium and 
was dispensed into a 75 cm
2
 cell culture flask. 
4. Cells were then incubated at 37 oC and 5% CO2 until 70-80% confluency (usually 
attained in 48 hours) was achieved. 
5. Sub culturing was done at 80% confluency by trypsinizing and resuspending the 
cells in new cell culture flasks containing the culture medium and incubated at 37 
o
C, 5% CO2
. 
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6. Cells were cultured as described above until sufficient numbers of viable cells 
were obtained for each experiment. Viability of cells was determined by Trypan 
blue exclusion assay and a hemocytometer.  
Preparation of CS samples: 
As described earlier, each CS sample was prepared in two different concentrations. Final 
concentrations of low and high concentration samples were 5 µg ml
-1
 and 15µg ml
-1
 
respectively. Samples were prepared by dissolving accurately weighed amounts of CS 
samples in complete cell culture media. All CS samples were completely soluble in the 
media. Prepared samples were aliquoted and stored at 2-8 
o
C until use. Samples were not 
stored beyond 7 days.  
LPS was also prepared in complete cell culture media. The stock solution was prepared to 
obtain a final concentration of 1 µg ml
-1
 LPS when 5 μl of this stock solution was added 
to the wells. Prepared LPS stock solution was stored at 2-8 
o
C.  According to the supplier, 
stability of LPS stock solution was estimated to be 4 months.   
Protocol for anti-inflammatory activity experiments: 
1. Costar 96 well tissue culture plates were plated with 105 cells/100 µl of 
complete cell culture media per well.  
2. The plates were then placed in an incubator at 37 oC and 5% CO2 for 18-20 
hours to ensure adhesion of cells to the tissue culture plate. 
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3. After 18 hours, the cell supernatant was aspirated and discarded. 100 µl of 
fresh complete cell culture media was added to the wells. 
4. After adding fresh media, the cells were incubated at 37 oC and 5% CO2 for 
another hour before adding the CS samples (low or high concentrations 
respectively). 
5. Forty five µl of CS samples (to sample wells) or blank media (to blank wells 
and LPS control wells) were added to the wells according to plate design. 
Each sample was plated in triplicate.  
6. Following the addition of CS samples, the plates were incubated at 37 oC and 
5% CO2 for one hour to facilitate uptake of CS by the RAW 264.7 cells. 
7. After this time, 5 µl of LPS was added to all wells except blank wells. 5 µl of 
complete cell culture media was added to blank wells. Plates were returned to 
the incubator and left for 4 hours. 
8. After 4 hours, the cell supernatant was carefully transferred into another 96 
well plate and stored at -20 
o
C until analysis for inflammatory biomarkers. 
9. Once the cell supernatant was removed, the MTS assay (see below) was 
performed on the cells to examine cell viability.  
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MTS assay for cell viability: 
CellTiter 96® AQueous One Solution reagent was thawed and a stock solution was made 
by combining the MTS reagent with cell culture medium according to the kit protocol. 
One hundred and twenty µl of stock solution was pipetted into each well containing the 
cells. The cells were then incubated at 37 
o
C, 5% CO2 in an incubator for 30-60 minutes 
to allow full color development. After incubation, the absorbance values (OD) of the 
samples in that 96 well plate were measured at 490 nm. The amount of colored product 
formed is proportional to the number of live cells in culture. Taking viability in blank 
wells (cells with no sample or LPS) as reference, percentage viability of cells treated with 
CS samples as well as cells treated with LPS was calculated using Equation 4.1. 
                                                                                                  ……............Equation 4.1 
Where, ODS is mean absorption of samples and ODB is mean absorption of blank. 
ELISA assays for TNF-α, IL-1β and IL-6: The protocols provided with Mouse Enzyme 
linked immunosorbent assay (ELISA) kits for TNF-α, IL-1β and IL-6 were followed to 
quantitatively determine the cytokines respectively. For detailed protocols, see 
Appendices 3, 4 and 5. 
Protocol for nitric oxide (NO):  
The level of NO production was monitored by measuring the nitrite concentration in cell 
culture supernatant. Griess reagent kit was used for quantification of nitrite. For this 
assay, the supernatant obtained in step 8 in the aforementioned procedure was used. The 
% cell viability = 100*(ODS / ODB)
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assay was performed according to the protocol provided with the kit. Refer to Appendix 6 
for detailed protocol.  
4.3 Results: 
Cell viability (MTS assay): 
As previously noted in methods, cell viability was calculated using Equation 7. 100% 
viability of cells was observed in cells treated with CS samples as well as cells treated 
with LPS only. This indicates that the CS samples were not toxic to the cells at the 
concentrations used (both low and high). 100% viability of cells treated with LPS alone 
indicates that LPS was not toxic to the cells at the concentration used. As could be seen 
from the results of the cytokine expression assays, 1μg/ ml concentration of LPS was able 
to stimulate an inflammatory response in RAW 264.7 cells without being excessively 
toxic and resulting in cell death. 
TNF-α:  
The levels of TNF-α were determined in blank samples, CS samples (low and high conc.) 
and LPS only samples following the procedure outlined in the methods section of this 
chapter. The samples were ranked in descending order of their TNF-α concentration for 
low conc. and high conc. CS samples respectively. Difference between samples was 
determined using t-test. Table 4.3.1 presents ranking of CS, blank and LPS samples in 
descending order of their TNF-α concentration values for CS at 5 μg/ml (low conc.) 
while Table 6 presents the same for CS at 15 μg/ml (high conc.). 
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Table 4.1: Ranking of CS samples (conc. 5 μg/ml) according to TNF-α concentration 
Samples compared by Student's t-test   
 
 
Note: Levels not connected by same Greek letter are significantly different. (p<0.05) 
From Table 4.1, it was noted that the TNF-α concentrations obtained for samples A, B, 
and H were significantly different from that of the LPS only samples. This indicated that 
the samples A, B and H, at concentration of 5 μg/ml, significantly lowered expression of 
TNF-α by the RAW-264.7 cells used in this study. Although the rest of the samples (C, 
D, E, F and G) also appeared to have TNF-α concentration lower than that of LPS, the 
difference was not significant. 
Sample Mean (conc. of TNF-α in pg/ml) 
LPS 232.14
(α) 
Sample D    186.33
(α)(β) 
Sample G 178.10
(α)β) 
Sample F 170.46
(α)(β) 
Sample E 168.98
(α)(β) 
Sample C 145.96
(α)(β) 
Sample H                                       139.75
(β) 
Sample B                                       123.99
(β) 
Sample A                                       117.96
(β) 
Blank 25.45
(γ) 
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Table 4.2: Ranking of CS samples (conc. 15 μg/ml) according to TNF-α concentration 
Samples compared by Student's t-test   
Sample Mean (conc. of TNF-α in pg/ml) 
LPS 232.14
(α) 
Sample H 215.24
(α)(β) 
Sample G 166.73
(α)(β)(γ) 
Sample D 140.76
(α)(β)(γ) 
Sample C 128.50
(α)(β)(γ)(δ) 
Sample E 122.51
(β)(γ)(δ) 
Sample F 114.62
(β)(γ)(δ) 
Sample A 111.08
(β)(γ)(δ) 
Sample B 84.60
(γ)(δ) 
Blank 25.45
(δ) 
 
Note: Levels not connected by same letter are significantly different. (P <0.05) 
At 15 μg/ml concentration, samples A, B, E and F significantly lowered expression of 
TNF-α by the RAW 264.7 cells used in this study. Samples C, D, G and H did not show 
significant lowering of TNF-α from LPS samples at this concentration. 
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Relationships between amount of TNF-α expressed and MW, % 6 sulfated disaccharides, 
% total sulfated disaccharides of CS samples: 
Bivariate fits were obtained to determine any correlations between percentage reduction 
in TNF-α values (of CS samples relative to LPS) and molecular weight, percentage 6-
sulfated fraction and, total sulfated fraction of CS in samples. ‗R2’ was used to assess the 
above mentioned relationships. R
2
 between 0.5 and 1.0 was considered high.  
The bivariate fits showed R
2 
< 0.5 indicating absence of any correlation between the 
percentage reduction of TNF-α and the MW of CS samples at both low and high 
concentrations of CS. Similarly, no correlation in percentage reduction of TNF-α with 
percentage 6-sulfated disaccharides at both high and low concentrations of CS were 
observed.  No correlation between TNF-α lowering and percent total sulfated 
disaccharides was observed at low CS sample concentrations (5 μg/ml). However, at a 
concentration of 15 μg/ml, there appears to be slight correlation between TNF-α lowering 
effect of CS and total sulfation (R
2
 = 0.58). But, as percentage of sulfated disaccharides 
did not vary much between the samples (range 89%- 93%), samples with a wider range of 
variable sulfated disaccharide percentages are needed to verify this relationship. 
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Figure 4.1: Percentage lowering of TNF-α by CS samples at low and high concentrations 
with respect to LPS only samples. 
Figure 4.1 summarizes the percentage lowering of TNF-α by CS samples of low and high 
concentrations with respect to TNF-α expressed by cells stimulated with LPS in the 
absence of CS samples. From this figure, it can be seen that all of the CS samples were 
more effective at 15 μg/ml concentration than at 5 μg/ml concentration in reducing the 
TNF-α, except sample H. Sample B, at 15 μg/ml concentration appeared to have the 
highest anti-inflammatory (AI) activity in terms of its ability to lower expression of TNF-
α and sample D appeared to have lowest AI activity. 
IL-1β: 
The levels of IL-1β were determined in blank samples, CS samples (low and high conc.) 
and LPS samples following the procedure outlined in the methods section. Samples were 
ranked in descending order of their IL-1β concentration for 5 μg/ml and 15 μg/ml CS 
samples respectively. Ranking was obtained by means comparison of each pair of 
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samples using student‘s t-test. Table 4.3 presents ranking of CS, blank and LPS samples 
in descending order of their IL-1β concentration values for CS at 5 μg/ml (low conc.) 
while Table 4.4 presents the same for CS at 15 μg/ml (high conc.). As seen from Tables 
4.3 and 4.4, the IL-1β produced by the macrophage cells in blank and LPS stimulated 
conditions was not significantly different from each other. Because of this, under the cell 
culture conditions and methods used in current experiments, IL-1β was not useful in 
estimating the anti-inflammatory activity of the CS samples. 
Table 4.3: Ranking of CS samples (conc. 5 μg/ml) according to IL-1β concentration 
Samples compared by Student's t-test   
Level Mean (conc. of IL-1β in pg/ml) 
Sample B 76.57
(α) 
LPS    73.18
(α)(β) 
Blank       56.46
(α)(β)(γ) 
 Sample C       53.84
(α)(β)(γ)
 
Sample H       51.93
(α)(β)(γ) 
Sample F        48.29
(α)(β)(γ) 
Sample E        38.13
(α)(β)(γ) 
Sample A        37.90
(α)(β)(γ) 
Sample G    26.91
(β)(γ) 
Sample D 25.01
(γ) 
 
Note: Levels not connected by same Greek letter are significantly different. (P <0.05) 
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Table 4.4: Ranking of CS samples (conc. 15 μg/ml) according to IL-1β concentration 
Samples compared by Student's t-test   
Level Mean (conc. of IL-1β in pg/ml) 
Sample C 116.39
(α) 
LPS       73.18
(α)(β) 
Sample H       61.74
(α)(β) 
Blank      56.46
(α)(β) 
Sample F      54.75
(α)(β) 
Sample B     53.50
(α)(β) 
Sample A 37.38
(β) 
Sample G 35.90
(β) 
Sample E 31.71
(β) 
Sample D 29.85
(β) 
 
. 
Note: Levels not connected by same letter are significantly different. (P <0.05) 
 
IL-6: 
The levels of IL-6 were determined in blank samples, CS samples (low and high conc.) 
and LPS samples following the procedure outlined in the methods section. The high 
concentration CS group and low concentration CS group were ranked separately in order 
of IL-6 production by the macrophages in the presence and absence of those samples. 
Ranking was obtained by means comparison of each pair using student‘s t-test. Table 4.5 
presents ranking of CS, blank and LPS samples in descending order of their IL-6 
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concentration values for CS at 5 μg/ml and Table 4.6 presents the same for CS at15 
μg/ml. 
Table 4.5: Ranking of CS samples (conc. 5 μg/ml) according to IL-6 concentration 
Samples compared by Student's t-test   
Level Mean (conc. of IL-6 pg/ml) 
Sample F 445.41
(α) 
Sample D    378.97
(α)(β) 
Sample A    354.11
(β)(γ) 
Sample C       325.17
(β)(γ)(δ) 
LPS       314.11
(β)(γ)(δ) 
Sample B       300.66
(γ)(δ)(ε) 
Sample E        264.94
(δ)(ε)(ϕ) 
Sample H     233.44
(ε)(ϕ) 
Sample G  223.86
(ϕ) 
Blank    35.10
(χ) 
 
Note: Levels not connected by same Greek letter are significantly different. (P <0.05) 
 As seen from Table 4.5, at 5 μg/ml CS concentration, baseline IL-6 produced by 
macrophages (from blank wells) is significantly less than that produced by the cells 
stimulated by LPS alone. However, cells incubated with some of the CS samples seem to 
have produced as much IL-6 as the LPS only cells. Samples, A, C, D and F, did not show 
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the IL-6 lowering effect. But, samples, B, E, G and H showed IL-6 levels less than that of 
LPS alone. Samples G and H especially were effective in lowering LPS stimulated IL-6.  
Table 4.6: Ranking of CS samples (conc. 15 μg/ml) according to IL-6 concentration 
Samples compared by Student's t-test   
Level Mean (conc. of IL-6 in pg/ml) 
Sample H 450.52
(α) 
Sample G 444.44
(α) 
LPS    314.11
(α)(β) 
Sample F    223.40
(β)(γ) 
Sample A      188.06
(β)(γ)(δ) 
Sample E         185.07
(β)(γ)(δ)(ε) 
Sample C     124.53
(γ)(δ)(ε) 
Sample D    49.82
(δ)(ε) 
Sample B    46.17
(δ)(ε) 
Blank 35.10
(ε) 
 
Note: Levels not connected by same Greek letter are significantly different. (P <0.05) 
At 15 μg/ml concentration, IL-6 produced by untreated cells was significantly lower than 
the levels produced by LPS only cells. As shown in Table 4.6, samples B, D and C 
significantly inhibited the amount of IL-6 produced by the LPS stimulated macrophage 
cells. Although cells treated with samples A, E and F produced lower IL-6 than LPS only 
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cells, the difference was not significant at P value of 0.05. Samples G and H did not show 
any IL-6 inhibiting effect.   
Relationship between amount of IL-6 expressed and MW, % 6 sulfated disaccharides, % 
total sulfated disaccharides of CS samples: 
Bivariate fits were obtained to determine any correlations between percentage reduction 
in IL-6 values (of CS samples relative to LPS) and molecular weight, percentage 6-
sulfated fraction and, total sulfated fraction of CS in samples. Correlation coefficients 
(R
2
) 0.5 to 1.0 were considered high.  
No correlation was observed between the IL-6 inhibiting effect and molecular weight of 
the CS samples (R
2
 = 0.115, P= 0.4) at 5 μg/ml concentration, although, at 15 μg/ml 
concentration, there appears to be a slight correlation with R
2 
of 0.52 (P= 0.042). No 
significant correlation seems to exist between % 6-sulfated disaccharides and inhibition 
of IL-6 of the CS samples at either 5 μg/ml (R2= 0.49, P= 0.05) or 15 μg/ml (R2= 0.22, 
P= 0.23) concentrations. Similarly, no correlations were observed between IL-6 
inhibiting effect and percentage of total sulfated disaccharides (R
2
=
 
0.34, 0.42 and, P= 
0.12, 0.08, respectively for low concentration and high concentration CS samples). 
Figure 4.2 summarizes the percentage lowering of Il-6 by CS samples of low and high 
concentrations with respect to IL-6 expressed by cells stimulated with LPS in the absence 
of CS samples. From this figure, it can be seen that all of the CS samples were more 
effective at 15 μg/ml concentration than at 5 μg/ml concentration in reducing IL-6, except 
samples G and H. Sample B, at 15 μg/ml concentration appeared to have the highest anti-
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inflammatory (AI) activity in terms of its ability to lower expression of IL-6. Although at 
5 µg/ml concentrations, samples A, C, D and F appear to increase Il-6 production 
compared to LPS stimulated cells, from table 4.5, it can be seen that the IL-6 values of 
those samples were not significantly different from that of LPS stimulated cells in the 
absence of CS samples. 
 
Figure 4.2: Percentage lowering of Il-6 by CS samples at low and high concentrations 
with respect to LPS only samples. 
 NO: 
NO was measured as the amount of nitrite in the samples. The levels of nitrite were 
determined in blank samples, CS samples (low and high conc.) and LPS samples 
following the procedure outlined in materials and methods section. The samples were 
ranked in descending order of their nitrite concentration for low concentration and high 
concentration CS samples separately. Ranking was obtained by means comparison of 
each pair using student‘s t-test. Table 4.7 presents ranking of CS, blank and LPS samples 
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in descending order of their nitrite concentration values for CS at 5 μg/ml (low conc.) 
while Table 4.8 presents the same for CS at 15 μg/ml (high conc.). 
Table 4.7: Ranking of CS samples (conc. 5 μg/ml) according to nitrite concentration 
Samples compared by Student's t-test   
Level Mean (conc. of nitrite in µM) 
Sample C 8.29
(α) 
Sample A 8.23
(α) 
Sample B     7.89
(α)(β) 
Sample G        7.78
(α)(β)(γ) 
Sample H         7.78
(α)(β)(γ) 
Sample E         7.65
(α)(β)(γ) 
Sample F         7.46
(α)(β)(γ) 
Blank      6.69
(β)(γ) 
Sample D      6.59
(β)(γ) 
LPS   6.33
(γ) 
 
Note: Levels not connected by same Greek letter are significantly different. (P <0.05) 
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Table 4.8: Ranking of CS samples (conc.15 μg/ml) according to nitrite concentration 
Samples compared by Student's t-test   
Level Mean (conc. of nitrite in µM) 
Sample C 17.038
(α) 
Sample G 12.80
(β) 
Sample D 12.70
(β) 
Sample H 12.36
(β) 
Sample A     10.12
(β)(γ) 
Sample B     10.09
(β)(γ) 
Sample E     10.03
(β)(γ) 
Sample F          9.29
(β)(γ)(δ) 
Blank       6.69
(γ)(δ) 
LPS     6.33
(δ) 
 
Note: Levels not connected by same letter are significantly different. (P <0.05) 
As seen from Tables 4.7 and 4.8, the base line nitrite values did not differ from the nitrite 
produced by the cells upon stimulation with LPS. This makes NO (measured as nitrite) 
ineligible to be considered a marker for anti-inflammatory activity; in RAW 264.7 cell 
line under the cell culture conditions used in this particular study. 
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CHAPTER 5 
DISCUSSION 
CS is used extensively as a treatment for OA in not just humans but also in animals such 
as horses and dogs in the United States and Europe (Luo et al., 2002; McAlindon et al., 
2000). It is currently recommended by EULAR as a SYSADOA in the treatment of knee 
and hand osteoarthritis based on research evidence and meta-analyses of numerous 
clinical studies (N. Volpi, 2009). The role of CS as part of the proteoglycan molecules is 
extended to crucial biological functions e.g., growth factor signaling, axonal growth and 
regeneration, neuritogenesis during CNS development, morphogenesis and cell division 
(Sugahara et al., 2003). It was also reported to be effective in lowering systemic 
inflammation associated with chronic inflammatory diseases such as cardiovascular 
diseases and rheumatoid arthritis (Herrero-Beaumont et al., 2008). As reported by several 
in vitro studies (G.M. Campo et al., 2008; G. M. Campo et al., 2009; Jomphe et al., 2008; 
F. Ronca, Palmieri, Panicucci, & Ronca, 1998), animal studies (Bauerova et al., 2011; 
Giuseppe M. Campo et al., 2003; Cho et al., 2004; Chou et al., 2005; Herrero-Beaumont 
et al., 2008; Taniguchi et al., 2012; Uebelhart, Thonar, Zhang, et al., 1998) and clinical 
trials (Bucsi & Poor, 1998) CS appears to play an important role in regulating cellular 
inflammatory events. 
The heterogeneity of CS was reported to play a role in its bioavailability and bioactivity 
(Nicola Volpi, 2011). In spite of its high molecular weight (MW 8- 44 kDa), absorption 
of CS had been reported in animal as well as in humans. Studies also reported absorption 
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of CS in its intact form (A. Adebowale et al., 2002; Barthe et al., 2004; Palmieri et al., 
1990). Several in vitro studies, animal studies, and clinical trials provided evidence that 
low molecular weight CS was more bio-available compared to its higher molecular 
weight counterparts (A. O. Adebowale et al., 2000; Conte et al., 1991; G. Ronca & 
Conte, 1993; N. Volpi, 2002, 2003).  
In this study, the effects of heterogeneity of CS on its absorption and anti-inflammatory 
activities were evaluated in vitro. As described in the earlier chapters in detail, 8 CS 
samples were compared in terms of their absorbability in Caco-2 monolayer and anti-
inflammatory activity in monocyte derived murine macrophages. Size exclusion 
chromatography (SEC) was used to determine the molecular weight of CS samples used 
in this study. CS samples of known molecular weight were used as the standards. As 
presented in Table 2.2, the molecular weights of sample A and B were calculated to be 7 
kDa and 8 kDa respectively. But, due to limited ability/sensitivity of SEC in separating 
samples very close to each other in size, it was difficult to obtain the absolute molecular 
weights of these samples (Trathnigg, 2006). Hence, samples A and B were evaluated 
based on quite similar, ―measured‖ molecular weights. Similarly, the sample pairs C-D, 
E-F, and G-H also had molecular weights that were comparable. 
Disaccharide composition of the CS sample was determined by the enzyme hydrolysis 
and HPLC-UV method. From the results listed in Table 2.3, it can be seen that although 
the samples differed from each other in % ΔDi-6S, they do not differ much in total 
sulfation (total % ΔDi). Samples B, G and H had higher % ΔDi-6S compared to the other 
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CS samples used in this study. Marine sources (shark) of CS have higher % ΔDi-6S 
compared to terrestrial sources (bovine, porcine) as outlined in table 1.1.  
The in vitro absorbability of the CS samples was measured in the Caco-2 cell line. Given 
its morphological and functional similarities to the enterocytes of small intestine, Caco-2 
has been used as a well-established model for conducting in vitro absorption studies by 
several pharma industries over the years. But, care needs to be taken in drawing 
conclusions regarding bioavailability of a compound in humans based on its absorbability 
in Caco-2 cells. This is because the correlation of the permeabilities of the slowly 
absorbed drugs in the Caco-2 monolayers and human intestine was qualitative rather than 
quantitative. Hence, Caco-2 proves to be a valuable resource when a series of compounds 
need to be ranked in order of their possible absorbability rather than calculate their 
absolute absorbability. Also, one should be cautious in comparing the permeability 
coefficients of compounds in Caco-2 lines between two different labs because of 
variation in cell line as well as cell culturing conditions. Even within the same lab using a 
standard protocol, variations were observed in absolute permeabilities of the same 
sample. This problem can be solved to an extent by including a standard with known 
absorbability (high or low) along with the samples being tested. Then, comparing the 
permeability coefficients of that standard with the same from other labs might provide an 
insight into how the cell layers compare between the labs.  
In the current absorbability study conducted with the CS samples, propranolol 
hydrochloride and sodium fluorescein were used as positive and negative controls 
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respectively. The Peff value of propranolol was 86.43 x 10
-6 
cm s
-1. 
The Peff values of the 
same compound reported by different labs was about 30 x 10
-6
 cm s
-1
  (Pade & 
Stavchansky, 1998; Yee, 1997). Compounds with Peff values over 10
-6 
were considered to 
be of high absorption with over 90% absorption in vivo and the ones with Peff < 10
-7
 were 
considered to have a very low absorption in vivo (Artursson et al., 2001). Positive and 
negative controls used in our experiments fulfill these requirements thus providing 
validity to the Peff values of CS samples. 
As seen from ranking of Peff of CS samples, Sample B has the highest absorption among 
the samples. As mentioned earlier, samples A and B were of similar molecular weights 
and hence a similar absorption profile was expected. Sample B, whose % ΔDi- 6S is 
higher than that of sample A showed higher permeability as well. In spite of their 
comparatively higher molecular weights, samples G and H show higher absorption than 
the lower molecular weight samples A, C, D and E and whose % ΔDi- 6S was lower than 
that of samples G and H. No correlation seems to exist between molecular weight and 
absorption in vitro within the molecular weights used in this study. The bivariate fit of 
Peff and % ΔDi- 6S in CS sample resulted in the R-square value of 0.5, P = 0.0477 which 
revealed that these two parameters were correlated, albeit weakly. This explains the 
absorption of shark chondroitin sulfate in humans in spite of its high molecular weight of 
44 kDa (N. Volpi, 2003).  Shark CS has a % ΔDi- 6S of about 50% (Mucci et al., 2000). 
Also, because of the lack of CS samples with pure ΔDi-4S in our sample set, no 
correlation data could be obtained for Peff  and % ΔDi-4S. However, given the significant 
effect of % ΔDi-6S on permeability and the lack of correlation with % total sulfated ΔDi, 
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it appears that presence of 4S has a tendency to negate positive effect of ΔDi-6S in CS 
absorbability. Further studies are needed to confirm this with samples of similar 
molecular weights and composed purely of either ΔDi-4S or ΔDi-6S. 
From the results of the AI study conducted using the same CS samples, it can be seen that 
all of the CS samples exhibited AI activity by inhibiting inflammatory cytokine 
production by the RAW 264.7 cells. Our results are in agreement with cytokine lowering 
effects of CS as reported by several researchers in in vitro studies (G. M. Campo et al., 
2009), and animal (Bauerova et al., 2011; Giuseppe M. Campo et al., 2003) studies. 
Although no correlations had been observed between the molecular weights, % ΔDi-6S 
or total % sulfated ΔDi and the anti-inflammatory activity, the ranking of samples 
according to their TNF-α and IL-6 levels provided us with samples with high AI activity 
among the set of CS samples used in this study.  
In humans, the physiological concentrations of 5 µg/ml and 15 µg/ml translate to a 
dosage of 400 mg of CS per day at approximately 8% and 20% absorption respectively, 
considering an average blood volume of 5 liters. At 5 μg/ml concentration, sample B 
ranked high among the samples in inhibiting the production of LPS stimulated TNF-α in 
RAW 264.7 cells. However, at the same concentration, the inhibition of IL-6 by sample B 
was not significant compared to LPS positive. At 15 μg/ml concentration, sample B 
stands out as the best among the CS samples by inhibiting production of both TNF-α and 
IL-6. The TNF-α lowering effect of CS samples appear to be dose dependent (higher 
percentage lowering of TNF-α at a higher concentration) except in case of sample H. The 
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IL-6 lowering effect of CS samples also appears to be better at 15 µg/ml concentration 
except in case of samples G and H.  
Although no clear correlation was identified between the molecular weights and 
percentage 6-sulfated disaccharides with absorption of the CS samples, our results show 
that sample B, which is a low molecular weight CS sample, with high (over 90%) 6-
sulfated disaccharide percentage had highest absorption and AI activity. A higher 
absorption than conventionally available CS would mean lower dosage would be 
sufficient in achieving plasma CS concentration with effective AI activity. Synthetic CS 
samples with predetermined molecular weights and disaccharide composition are needed 
to verify correlations between absorption and molecular weight as well as disaccharide 
composition. This could be an objective for future studies. 
In summary, this study employed, CS, a highly heterogenous molecule, to evaluate and 
verify the usage of in vitro models of absorption and AI activity as screening tools for 
ranking CS samples based on their permeability and cytokine inhibitory effect. Our 
results suggest that the aforementioned models can indeed be used as screening tools to 
identify prospective candidates for future clinical trials.  
Another important outcome of this study was development of a screening tool that could 
be employed prior to clinical trials for selecting potential compounds to be included in 
the trial. It is common knowledge that clinical trials can be extremely expensive. This 
cost proportionately increases with an increase in the number of samples to be evaluated. 
The combination of in vitro studies employed in this project may be used as a guiding 
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tool in identifying the compounds that are most likely to be effective in clinical studies. 
Such an in vitro screening tool lowers the expense incurred by the clinical trials by 
several fold by reducing the number of samples to be evaluated in vivo. This is of 
particular importance for nutrition supplement manufacturers where different 
formulations of same nutrients may need to be evaluated based on their bioavailability 
and functionality.  
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Appendix 1 
Materials and methods for the determination of molecular weights of CS samples 
Preparation of standards and samples:   
1. Known molecular weight CS standards were prepared by dissolving 20 mg of CS 
standard in 10 ml of HPLC grade water.  
2. An internal standard was also prepared by dissolving 20 mg of inosine (Sigma, 
Catalog # I4125) in 10 ml of HPLC grade water.  
3. Working standards were prepared in a HPLC vial by adding 200 µl of internal 
standard solution to 800 µl of CS standard. 
4. To prepare working samples, about 20 mg of each sample was weighed into a 10 
ml volumetric flask and 250 µl of internal standard (2 mg/ml inosine solution 
from step 3) was added to it. The solution was then made up to a volume of 10 ml 
with HPLC grade water. These sample solutions were filtered through 0.45 
micron filters. 
HPSEC conditions:  
1. High performance liquid chromatography (HPLC) instrument- Waters, Part # 
2. Columns- Two Agilent Bio SEC-3 (150 x 7.8 mm) columns packed with 3 μm 
silica particles coated with a proprietary neutral, hydrophilic layer with pore sizes 
150 Å and 100 Å  (Agilent, Part # 5190-2507 and # 5190- 2502) were connected 
in tandem.  
3. Mobile phase – 80% buffer and 20% ethanol was used as a mobile phase.  
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The buffer was prepared by making a solution of 30mM Disodium hydrogen 
phosphate (Na2HPO4, Fisher Scientific, Catalog # S374) and 30 mM Sodium 
sulfate (Na2SO4, JT Baker, Catalog # 3898-01). The pH of this solution was 
adjusted to 7 using 0.1 N phosphoric acid(H3PO4).  
4. Injection volume of 5 µl was set for both standards and samples. 
5. Column temperature was set at 35 oC, flow rate was set at 1.0 ml/min and run 
time was set for 15 minutes. 
6. UV signal was detected at 205 nm using a photo diode array detector (Waters,) 
Protocol for determination of standard curve: 
1. Each working standard was injected once and chromatograms were recorded.  
2. For each chromatogram, retention volumes were calculated for CS standard as 
well as internal standard according to equation A.1.1: 
                                                                           ………………… Equation A.1.1 
Where, RV = retention volume of CS standard or internal standard, RT = retention time 
of the component (CS standard or internal standard), and flow rate = 1.0 ml/min  
3. The standard curve was obtained by plotting a graph with the ratio of RV of 
internal standard (RVis) and RV of standard ( RVstd ) as abscissa (x-axis) and log 
MW as ordinate (y-axis). A third degree polynomial equation was calculated (in 
the form of Equation A.2) from the data. 
                                                                                                                   …Equation A.1.2 log MW = a(RVis / RVstd)
3
 + b(RVis / RVstd)
2
 + c(RVis / RVstd) + d 
RV = RT X flow rate 
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Calculation of molecular weights of CS samples (of unknown MW): 
1. CS samples were also run under the same chromatographic conditions as 
standards and RTs of the CS samples and internal standard were obtained from 
their chromatograms. 
2. RVs of CS samples and internal standards were calculated using their respective 
RTs in equation A.1. 
3. RVs obtained in the above step were substituted in the standard curve (Equation 
2) to calculate log MW of CS samples.  
4. MW of CS samples were calculated using Equation A.3 
                                                                                             ……..…Equation A.1.3 
 
 
 
 
 
 
 
 
 
 
 
 
MW (in kilo Daltons) = 10
log MW
 / 1000 
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Appendix 2 
Materials and methods for the determination of disaccharide composition of CS 
samples  
Preparation of reagents: 
1. Mobile phase A- 340 mg of tetrabutylammonium bisulfate (Sigma, Catalog # 
86868) was dissolved in 1000 ml of water (HPLC grade). 
2. Mobile phase B- 340 mg of tetrabutylammonium bisulfate was dissolved in 330 
ml water and acetonitrile (HPLC grade) was added to make up the volume to 
1000 ml.  
3. Tris- (hydroxymethyl) aminomethane (TRIS) buffer solution- 3g of TRIS (Sigma, 
Catalog # T1503), 2.4 g of anhydrous sodium acetate (Sigma, Catalog # S8750), 
1.46 g of sodium chloride (ACS reagent grade) and 50 mg crystalline bovine 
serum albumin (Sigma, Catalog # A4378) were accurately weighed and dissolved 
in 100 ml of 0.12 M HCl. pH of this solution was adjusted to 7.3 with 6M HCl 
(HPLC grade). 
4. Chondroitinase AC II enzyme solution- 5 units of chondroitinase AC II enzyme 
(Seikagaku America, Catalog # 100335-1A) was dissolved in 0.5 ml water. 
Enzyme was stored at < 0 
o
C when not in use. 
Preparation of standards and samples: 
1. Chondroitin sulfate disaccharide reference standards (non-sulfated or ΔDi-0S, 4-
sulfated or ΔDi-4S and 6- sulfated or ΔDi-6S) were purchased from Sigma 
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(Catalog # C3920, C4045 and C4170 respectively). Stock solution of these 
disaccharide standards were prepared by dissolving 2mg of ΔDi-0S and 10 mg 
each of ΔDi-4S and ΔDi-6S in 50 ml of water.  
2. Serial dilution of disaccharide stock solution was done to obtain standard 
disaccharide solutions with concentrations of ΔDi-4S and ΔDi-6S between 2 - 100 
μg/ml and ΔDi-0S between 0.4 - 20 μg/ml. 
3. One hundred mg of CS samples were accurately weighed and dissolved in 50 ml 
of water in separate volumetric flasks.  
Enzymatic hydrolysis of CS samples: 
1. Twenty μl of TRIS buffer solution, 30 μl of enzyme solution and 20 μl of CS 
sample were pipetted into 0.5 ml eppendorf tubes.  
2. The Eppendorf tubes were then incubated in a water bath at 37 oC for 3 hours. 
3. Once removed from water bath, the samples in eppendorf tubes were allowed to 
cool to room temperature. 230 μl of mobile phase A was added to the tubes and 
the hydrolyzed CS solution was transferred into 2 ml HPLC vials. The eppendorf 
tubes were rinsed with another 200 μl of mobile phase A which was transferred 
into the HPLC vial with hydrolyzed CS solution. Another 500 μl of mobile phase 
A was added to those vials and mixed well. 
HPLC analysis of hydrolyzed CS samples: 
1. Waters HPLC machine connected to a PDA detector (Waters, Part # 2996) was 
used to analyze the CS disaccharide standards and CS samples. 
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2. Phenomenex SynergiTM Polar-RP, 4.6 x 150 mm, 4 μm column was equilibrated 
with 80 % mobile phase A and 20% B. The following mobile phase gradient was 
followed to run the standards/samples (Table A.2.1). 
Table A.2.1: Mobile phase gradient for CS disaccharide analysis 
Time, min % mobile phase A % mobile phase B 
0 
0 – 7.0 
7.0 – 12.0 
12.0 – 12.5 
80 
35 
35 
80 
20 
65 
65 
20 
   
3. Standards and samples were injected at an injection volume of 20 μl and a 
runtime of 20 minutes. Detection was done at 240 nm. 
4.  Empower 3 software was used to calculate concentrations of individual 
disaccharides using concentrations of disaccharide standards.  
5. For each CS sample, total CS was measured as a sum of ΔDi-0S, ΔDi-4S and 
ΔDi-6S.  
6. Percentage of ΔDi-0S in each CS sample was calculated using Equation A.2.1. 
                                                                                                 …Equation A.2.1 
7. Percentages of 4-sulfated and 6-sulfated disaccharides were calculated by 
substituting conc. of ΔDi-0S with conc. of ΔDi-4S and ΔDi-6S respectively in 
Equation A.2.1. 
 
% ΔDi-0S = 100 x (Conc. of ΔDi-0S / Total CS conc.) 
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Appendix 3 
Protocol for TNF-α ELISA 
Steps for determination of TNF-alpha in cell supernatant samples: 
1. The supernatant samples from anti-inflammatory activity were used in this assay.  
2. All the kit contents were allowed to reach room temperature before performing 
the assay. 
3. TNF-α standards, high/low controls, streptavidin-horse radish peroxidase (Strp-
HRP) and wash solution were prepared according to the manufacturer instruction 
manual. 
4. For the standard curve, 100 µl of standards were added to the appropriate 
microtiter wells. 100 µl of standard diluent buffer was added to the zero standard 
well. Chromogen blank sample wells were left empty. 
5. Controls and cell supernatant samples needed to be diluted two fold in standard 
diluent buffer. 50 µl of samples and controls were added to the appropriate wells 
followed by 50 ul of standard diluent buffer. The plate was tapped gently on the 
side to mix. 
6. Fifty µl of biotinylated mouse TNF-α- biotin conjugate solution was pipetted into 
each well except chromogen blank wells and mixed gently. 
7. The plate was then covered and incubated at room temperature for 90 minutes.  
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8. After 90 minutes, the solution was aspirated thoroughly, decanted and discarded. 
The wells were washed 4 times and placed upside down on an absorbent paper 
towel for few minutes. 
9. One hundred µl of Strp-HRP working solution was added to each well except 
chromogen blank wells. The plate was then covered and incubated for 30 minutes 
at room temperature. 
10. After 30 minutes, the solution was aspirated and discarded. The plate was washed 
four times and placed on an absorbent paper for drying. 
11. One hundred µl of stabilized chromogen was added to each well. The liquid in the 
wells started to turn blue. The plate was covered and incubated in the dark at 
room temperature for 30 minutes.  
12. One hundred µl of stop solution was added to each well after 30 minutes. The side 
of the plate was tapped gently to mix. The solution in the wells turned from blue 
to yellow.  
13. The absorbance of each well was read at 450 nm having blanked the plate reader 
against the chromogen blank wells.  
14. A standard curve was plotted with the OD values of TNF-α standards (0 pg/ml- 
1000 pg/ml) and their concentrations. The equation of standard curve was then 
used to determine concentrations of TNF-α in the cell supernatant samples. 
15. The calculated concentrations were then multiplied with a dilution factor two to 
obtain the original concentrations of TNF-α in the cell supernatant samples.  
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Appendix 4 
Protocol for IL-1β ELISA 
Steps for determination of IL-1β in cell supernatant samples: 
1. The supernatant samples from anti-inflammatory activity were used in this assay.  
2. All the kit contents were allowed to reach room temperature before performing 
the assay. 
3. IL-1β standards, high/low controls, streptavidin-horse radish peroxidase (Strp-
HRP) and wash solution were prepared according to the manufacturer instruction 
manual. 
4. Fifty µl of the incubation buffer was added to all wells except the chromogen 
blank wells. 
5. For the standard curve, 50 µl of standards were added to the appropriate 
microtiter wells. Fifty µl of tissue culture media was added to the zero standard 
well. Chromogen blank sample wells were left empty. 
6. Controls and cell supernatant samples needed to be diluted two fold in standard 
diluent buffer. 50 µl of samples and controls were added to the appropriate wells 
followed by 50 µl of tissue culture media. The plate was tapped gently on the side 
to mix. 
7. Fifty µl of biotinylated mouse IL-1β- biotin conjugate solution was pipetted into 
each well except chromogen blank wells and mixed gently. 
8. The plate was then covered and incubated at 37 oC for 90 minutes.  
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9. After 90 minutes, the solution was aspirated thoroughly, decanted and discarded. 
The wells were washed 4 times and placed upside down on an absorbent paper 
towel for few minutes. 
10. One hundred µl of Strp-HRP working solution was added to each well except 
chromogen blank wells. The plate was then covered and incubated for 30 minutes 
at room temperature. 
11. After 30 minutes, the solution was aspirated and discarded. The plate was washed 
four times and placed on an absorbent paper for drying. 
12. One hundred µl of stabilized chromogen was added to each well. The liquid in the 
wells started to turn blue. The plate was covered and incubated in the dark at 
room temperature for 30 minutes.  
13. One hundred µl of stop solution was added to each well after 30 minutes. The side 
of the plate was tapped gently to mix. The solution in the wells turned from blue 
to yellow.  
14. The absorbance of each well was read at 450 nm having blanked the plate reader 
against the chromogen blank wells.  
15. A standard curve was plotted with the OD values of IL-1β (0 pg/ml- 1000 pg/ml) 
and their concentrations. The equation of standard curve was then used to 
determine concentrations of IL-1β in the cell supernatant samples. 
16. The calculated concentrations were then multiplied with a dilution factor two to 
obtain the original concentrations of IL-1β in the cell supernatant samples.  
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Appendix 5 
Protocol for IL-6 ELISA 
Steps for determination of IL-6 in cell supernatant samples: 
1. The supernatant samples from anti-inflammatory activity were used in this assay.  
2. All the kit contents were allowed to reach room temperature before performing 
the assay. 
3. IL-1β standards, high/low controls, streptavidin-horse radish peroxidase (Strp-
HRP) and wash solution were prepared according to the manufacturer instruction 
manual. 
4. For the standard curve, 100 µl of standards were added to the appropriate 
microtiter wells. 100 µl of standard diluent buffer was added to the zero standard 
well. Chromogen blank sample wells were left empty. 
5. Controls and cell supernatant samples needed to be diluted two fold in standard 
diluent buffer. 50 µl of samples and controls were added to the appropriate wells 
followed by 50 µl of standard diluent buffer. The plate was tapped gently on the 
side to mix. 
6. The plate was then covered and incubated at room temperature for 2 hours.  
7. After 2 hours, the solution was aspirated thoroughly, decanted and discarded. The 
wells were washed 4 times and placed upside down on an absorbent paper towel 
for few minutes. 
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8. One hundred µl of biotinylated mouse IL-6- biotin conjugate solution was 
pipetted into each well except chromogen blank wells and mixed gently. 
9. The plate was then covered and incubated at room temperature for 30 minutes.  
10. After 30 minutes, the solution was aspirated thoroughly, decanted and discarded. 
The wells were washed 4 times and placed upside down on an absorbent paper 
towel for few minutes. 
11. One hundred µl of Strp-HRP working solution was added to each well except 
chromogen blank wells. The plate was then covered and incubated for 30 minutes 
at room temperature. 
12. After 30 minutes, the solution was aspirated and discarded. The plate was washed 
four times and placed on an absorbent paper for drying. 
13. One hundred µl of stabilized chromogen was added to each well. The liquid in the 
wells started to turn blue. The plate was covered and incubated in the dark at 
room temperature for 30 minutes.  
14. One hundred µl of stop solution was added to each well after 30 minutes. The side 
of the plate was tapped gently to mix. The solution in the wells turned from blue 
to yellow.  
15. The absorbance of each well was read at 450 nm having blanked the plate reader 
against the chromogen blank wells.  
16. A standard curve was plotted with the OD values of IL-6 (0 pg/ml- 500 pg/ml) 
and their concentrations. The equation of standard curve was then used to 
determine concentrations of IL-6 in the cell supernatant samples. 
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17. The calculated concentrations were then multiplied with a dilution factor two to 
obtain the original concentrations of IL-6 in the cell supernatant samples.  
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Appendix 6 
Protocol for nitrite estimation 
1. Standard solutions of sodium nitrite (NaNO2) with concentrations ranging from 0 
µM to 100 µM were prepared in DI water.  
2. In a 96 well plate, 20 μl of Griess reagent, 150 μl of the supernatant (or NaNO2 
standards), and 130 μL of deionized water were added.  
3. In photometric reference wells, 20 μL of Griess Reagent and 280 μL of deionized 
water were added.  
4. After mixing the above reagents, the plate was covered and incubated for 30 
minutes at room temperature. 
5. After 30 minutes, the absorbance (OD) of the azo dye formed in the reaction as 
measured using a plate reader at 520 nm. 
6. A standard curve was obtained using the concentrations and OD values of the 
NaNO2 standards. 
7. The standard curve was used to calculate nitrite concentrations of samples from 
cell supernatants.  
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